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ABSTRACT 
 
     Antisense oligodeoxynucleotides (AS ODNs) are short single-stranded pieces of DNA that 
are designed to hybridize with messenger RNA and thus offer a powerful technique for 
controlling gene expression.  Phosphorothioate AS ODNs are a well-established modification of 
the traditional phosphodiester structure that increase the in vitro half-life of AS ODN activity.  In 
this work, we describe a method for controlling the hybridization activity of PS ODNs in cell 
culture with a photo-reversible mechanism.  The influence of a photocaging compound, 1-(4,5-
dimethoxy-2-nitrophenyl)diazoethane (DMNPE) on hybridization of ISIS 2302, a 20-mer PS 
ODN, was modeled using a molecular beacon assay.  Based on this model, a relationship 
between the number of attached cage groups and the inactivation of hybridization activity was 
established.  In addition, the light-dose effects on cell morphology and intracellular adhesion 
molecule-1 (ICAM-1) target protein expression levels were used to determine that 40 J/cm2 of 
UVA light was the maximum dose that could be used for photorestoration of antisense activity in 
cell based studies.   Active and DMNPE-inactivated forms of ISIS 2302 were delivered to human 
epithelial carcinoma (HeLa) cells.  78 ± 2.9% of cells exposed to active ISIS 2302 showed 
decreases in cytokine-stimulated ICAM-1 protein expression as measured by flow cytometry.  
However, only 25 ± 1% of cells exposed to DMNPE-inactivated ISIS 2302 experienced 
antisense effects.  Subsequent exposure of HeLa cells to 40 J/cm2 of 365 nm light resulted in 
photo-restoration of cage-inactivated ISIS 2302 antisense activity in 56.7 ± 5.9% of HeLa cells.  
There was no significant difference in ICAM-1 expression between cells treated with 40%-caged 
antisense and cells treated with no antisense.  Subsequent exposure to 40 J/cm2 365 nm light 
resulted in a significant increase in antisense activity from the cells treated with 40%-caged 
 xi 
antisense.  This work demonstrates the in vitro use of a light inducible system for achieving the 
spatio-termporal control of antisense specific activity. 
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CHAPTER I 
 
BACKGROUND AND INTRODUCTION 
 
Introduction 
 
     Caged compounds are an optically-active class of chemicals that have been designed to 
respond to light in the UV and near-UV range. Upon exposure to light, the photolabile bond 
between the cage species and its target molecule is cleaved, releasing the target molecule to its 
“native” original, bioactive form.  Photosensitive cage compounds have been shown to 
successfully inactivate DNA plasmid activity in vitro and in vivo (Monroe, McQuain, et al., 
1999). The mechanism of inactivation involves the covalent attachment of a chemical cage 
species to the DNA effector molecule via a photolabile bond. The subtle influence of the cage 
group on the structure of the DNA molecule renders DNA biologically inert. The cage 
compound 1-(4,5-dimethoxy-2-nitrophenyl)ethyl ester (DMNPE) has previously been used  in 
the control of various biological molecules including ATP and phosphodiester 
oligodeoxynucleotides (ODNs) (Kaplan, Forbush, et al., 1978; Walker, Reid, et al., 1988; Ghosn, 
Haselton, et al., 2005).  The high efficiencies achieved in cage reactions involving 20 mer ODNs 
suggested that ODNs of the same sequence but having modified backbone structures would also 
be suitable candidates to be cage-inactivated by DMNPE.  Preliminary investigations showed 
that the hybridization activity of the phosphodiester ODNs could be significantly reduced 
through the attachment of DMNPE and that this activity can be photo-restored through exposure 
to near-UV light (Ghosn, Haselton, et al., 2005).  Achieving control over the hybridization 
abilities of nucleic acids translates to control over biological activity and gene expression. 
      One area of potential use of caging chemistries is in achieving the targeted delivery of 
antisense therapeutics.  Antisense gene therapy has evolved out of a refocusing of medicinal  
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therapeutic strategies from the protein to the DNA level. Antisense strategies offer the advantage 
of specificity with direct targeting of diseased and damaged genes. However, the current 
challenge in the implementation of antisense therapeutics lies in achieving spatial and temporal 
control over the range of their inhibitive effects.  Cage-inactivation and subsequent photo-
restoration of antisense agents is one possible means of achieving this control.  ISIS 2302 is one 
such antisense agent, a 20-mer phosphorothioate DNA sequence, which suppresses the cell 
surface expression of Intracellular Adhesion Molecule-1 (ICAM-1) in vivo.  For in vitro 
experimentation, ISIS 2302 has been shown to suppress ICAM-1 expression in cells stimulated 
with various cytokines, including Interferon-γ, tumor necrosis factor-α, and interleukin-1β 
(Dustin, Rothlein, et al., 1986; van de Stolpe, van der Saag, 1996).   This study proposes to test 
the effectiveness of a cage-inactivated ISIS 2302 antisense system in cell culture and 
demonstrate that significant photo-restoration of antisense activity can occur with minimal cell 
damage through the optimization of caging reaction conditions.  
The Promise of Gene Therapy: Prophylactic Action 
     Conventional drug therapies are designed to target post-translational products in their 
direction to quench the effects of mutations, disease, and infections. Gene therapy treatments 
have advanced the potential of drug therapy through their mechanism of action which works to 
inhibit the expression of a mutation that is causing a particular disease or infection rather than 
treating the effect of the mutation.  In addition, the high specificity associated with genetic 
treatments offers the additional advantage of decreased incidence of the side effects that are 
commonly associated with conventional therapeutics.  The general goal of gene therapy is to treat 
disease, either by curing the disease or slowing progression, through the introduction of specific  
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genetic materials targeted to specific cells or tissues (Mulligan, 1993).  Genetic treatments may 
involve nucleic acids in the form of antisense oligodeoxynucleotides, double-stranded plasmids, 
DNA aptamers, or DNAzymes which work through cleavage or splicing mechanisms, or as RNA 
in the form of ribozymes which are enzymatically active RNA, RNA aptamers which work 
through direct protein inhibition, or RNA interference (Patil, Rhodes, et al., 2005).  
     Implementation of these genetic strategies depends on the ability to introduce transgenes into 
cells.  Introduction of these genes in naked form to solutions in cell culture rarely results in 
successful uptake and there is minimal endosomal release of the few internalized ODNs (Patil, 
Rhodes, et al., 2005; Roth, Sundaram, 2004).  Therefore, a delivery mechanism is necessary to 
transport and establish transgenes in cells.  Gene therapy delivery systems fall into one of two 
major classifications:  physical techniques or vector delivery techniques.  Physical techniques 
refer to the delivery of naked ODNs via microinjection, particle bombardment, electroporation 
and other such strategies.  The major advantages of these systems are the very high level of 
specificity in delivery, ability to achieve single cell targeting, and, with the exception of 
bombardment techniques, high efficiency.  Despite these advantages, practical considerations 
concerning ease of use, transfection time and, risk to cell viability render them less desirable 
candidates as delivery systems than the vector techniques in many applications (reviewed by 
Wells, 2004; Patil, Rhodes, et al., 2005).   
     Alternatively, vector systems, though less efficient, offer the advantages of being non-
invasive and providing additional protection from nuclease digestion. Vector systems can be 
classified as either viral or non-viral vectors and have been reviewed by Patil et al (Patil, Rhodes, 
et al., 2005).  Adeonviral vectors are double-stranded DNA vectors that are popular due to their 
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efficiency and ability to transmigrate dividing and non-dividing (senescent) cells (Liu, 
Nakamura, et al., 2006).  However, adenoviral vectors are highly immunogenic and desired 
genetic effects are rapidly neutralized through their uptake by the reticuloendothelial system and 
liver (Liu, Nakamura, et al., 2006).  Adeno-associated vectors are single-stranded relatives of 
adenoviral vectors that have reduced risk of inciting an acute immune response.  However, their 
use is limited by small loading capacity and restrictions on the types of cells that they can 
transfect (Nicklin, Buening, et al., 2001).  Retroviral vectors offer the advantage of being able to 
sustain expression due to integration into the cellular genome.  In addition, retroviral vectors can 
be specifically targeted to various tissue types, but even so these vectors preferentially uptake 
into rapidly dividing cells.  The disadvantage to the use of retroviral vectors is the increased risk 
of cancer development, specifically leukemia (Liu, Nakamura, et al., 2006).   Lentiviral vectors 
are a subclass of retrovirals that are specifically derived from the human immunodeficiency virus 
and have the ability to transfect non-dividing as well as dividing cells.   However, the 
disadvantage to these vectors is their lack of targeting ability, especially when target cells are 
dispersed throughout the body.  
     Natural and synthetic polymers, lipids, and ligands are several types of non-viral vectors used 
for DNA transport.  Polymeric delivery systems are well studied and nano-technological 
advances have broadened their applicability through the fine-tuning of hydrolysis and diffusion 
rates.  A biodegradable polymer can be chosen such that specific release rates can be achieved 
while protecting the entrapped ODNs from nuclease digestion.  Many commercially available 
DNA transfection agents are composed of neutral, anionic, and/or cationic lipid derivatives.  
Cationic liposomes are easy to use due to their self-assembling nature allowing DNA complexes 
to be formed relatively quickly and achieve high transfection efficiencies (Roth, Sundaram, 
2004).  However, the efficiencies achieved with any delivery system depend on experimental 
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conditions.  Choice of cell type, incubation times, and most importantly, the class and chemical 
makeup of the nucleic acid being used will influence the effectiveness of the carrier system. 
Gene Silencing: Antisense 
 
      Antisense is a sequence-specific form of genetic therapy that works towards inhibiting target 
gene expression.  Antisense agents utilize specific sequence information derived from functional 
genomics and thus have very high specificity and broad applicability in a variety of areas from 
target validation to therapeutics (Kurreck, 2003; Bennett, Cowsert, 1999).  The antisense mode 
of action is based on the central dogma of molecular biology which describes protein production 
though DNA transcription and RNA translation.  During transcription, DNA localized in the 
nucleus is unwound gene-by-gene into two individual strands, a sense and an antisense strand. 
Messenger RNA (mRNA) is created from the sense strand of the unwoven DNA molecule.  Once 
the complete gene has been transcribed, the mRNA migrates from the nucleus into the cytoplasm 
and conjugates with ribosomes.  The mRNA-ribosome complex translates the information 
encoded on the mRNA to produce nucleic acids that are elongated to form a protein.   
     Antisense strategies modulate protein production through the down-regulation of gene 
expression based on selective inhibition. Antisense technology is based on the generation of a 
short nucleotide sequence (between 15 – 25 base pairs) which is complementary to a target 
mRNA sequence (Cook, 1993). These highly specific sequences are synthetically engineered to 
model regions on the non-coding strand of unwound DNA double helix and are therefore 
complementary to specific mRNA sequences.  With the elucidation of the complete human 
genome, an antisense ODN could conceivably be designed to target any gene combination to 
treat any disease.   
     Once introduced into the cell, the antisense ODN binds to the target mRNA via Watson-Crick 
hydrogen bonding.  The resulting heteroduplex works to inhibit translation by one of two 
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methods.  One route of antisense activity is through the steric blockade of translation at the 
ribosome. Initial observations of antisense effects were demonstrated when researchers observed 
the inhibition of Rous sarcoma virus replication by a complementary oligonucleotide through 
this steric blockade mechanism (Zamecnik, Stephenson, 1978).  The second and more powerful 
means of antisense activity is the induction of ribonuclease H (RNase H)–dependent cleavage of 
mRNA.  When antisense ODNs bind to their mRNA target, the double-stranded complex that is 
formed though the binding of mRNA to the antisense ODN is a cellular aberrance that stimulates 
the activity of RNase  H.  The RNase  H enzyme selectively degrades the mRNA strand of the 
mRNA-ODN heteroduplex and releases the antisense ODN into the cytoplasm to bind to its next 
target (Nakamura, Oda, et al., 1991; Wu, Lima, et al., 2004).  One of the advantages of the 
RNase H mechanism is that ODN association with mRNA offers the ODN protection from 
nuclease digestion.   
     In general, there are several requirements that an antisense therapeutic needs to meet and 
certain characteristics that define their effectiveness.   Antisense ODNs must be able to get 
through the cell membrane, be able to integrate with the aqueous environment, and have the 
ability to distribute to the cell cytoplasm and/or nucleus where their effects are carried out.  In 
order to produce any effect, the ODN needs to have an improved resistance to nuclease 
degradation without compromising its specificity or its binding affinity to the target mRNA.   In 
comparisons between mechanisms of inhibition, it is generally desirable that the ODN induce 
RNase H target degradation (Grunweller, Wyszko, et al., 2003) despite the rare exceptions where 
steric inhibition has been shown equally potent (Kurreck, Wyszko, et al., 2002). 
Antisense Oligonucleotide Variations 
     Chemical modifications to AS ODNs are designed to promote the characteristics outlined 
above to enhance their effectiveness.   Limitations associated with the biostability of normal 
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phosphodiester AS ODNs are related to the poor in vivo half-life due to their rapid degradation 
by both extraellular and endocellular nucleases (Cook, 1993).  Nuclease affinity for antisense 
agents can be greatly reduced though the modification of the phosphodiester backbone.  
Modifications to the physical structures of antisense ODNs typically involve replacing one of the 
non-bridging oxygen atoms with an alternative chemical group.  Several of these chemical 
modifications are shown in Figure 1.1.  First generation structural modifications include 
phosphorothioate ODNs (PS ODNs), which have sulfur-substituted linkages, and 
phosphorodiamidate morpholinos, shown in Figure 1.1. Phosphorothioates have been the most 
extensively studied modification due to the ease of synthesis and their commercial availability. 
Phosphorothioates also remain the most widely employed antisense therapeutic as they are one 
of the few modifications whose chemical makeup is a suitable substrate for RNase H (Wu, Lima, 
et al., 2004;Kurreck, 2003).  In addition, the increased nuclease resistance of phosphorothioate  
 
 
Figure 1.1.  Oligonucleotide Backbone Modifications 
ODNs allows for an intracellular half-life on the order of several hours compared to only several 
minutes with normal PD-ODNs (Maksimenko, Gottikh, et al., 1999).  However, PS ODNs have 
disadvantages associated with compromised binding affinity and reduced specificity for the 
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target mRNA resulting from the increased binding affinity for certain proteins in the extracellular 
matrix, blood plasma, and serum (Brown, Kang, et al., 1994; Maksimenko, Gottikh, et al., 1999).  
In addition, uncertainty concerning basic mechanisms of action has caused some concern about 
the possible toxicity of PS ODNs as they are degraded (Crooke, 2004).  However, oxidation of 
thiol groups on the PS backbone result in normal phosphodiester structure with no inherent 
toxicity (Crooke, 2004). 
     Second and third-generation modifications likewise have increased nuclease resistance and 
may offer improved specificity over first-generation phosphorothioates.  An in-depth study of a 
second-generation modification in which a PS is modified with a 2’-O-methyl chimera 
demonstrated equal cellular stability and a ten-fold increase in target specificity over that 
achieved with an unmodified PS (Yoo, Bochkareva, et al., 2004). In this comparative study 
between first-generation unmodified PS and second-generation 2’-O-Methyl modified PS, Yoo 
et al were able to quantify the decrease of RNase H activation reporting a 50% decrease in 
mRNA target degradation when the modified PS ODNs were used (Yoo, Bochkareva, et al., 
2004).      Likewise, third-generation modifications, such as peptide nucleic acids (PNAs) and 
morpholinos have received notable attention for both their high specificity and definitive non-
toxicity (Nesterova, Cho-Chung, 2004; Summerton, 1999).  In addition, both of these modified 
ODNs are completely resistant to nuclease digestion because, in the case of PNAs, the entire 
phosphate backbone has been replaced with peptides, and in the second case, the ribose has been 
replaced with a morpholino group thus rendering both unrecognizable by nucleases.  However, 
there have also been cases of evidence to the contrary in which the long-term effectiveness of PS 
ODNs dominates over several other modification types including PNAs (Gray, Basu, et al., 
1997).  It is difficult to achieve a true comparison of efficacies between the uncharged third-
generation PNAs and morpholinos and the negatively charged second-generation 
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phosphorothioates because of the extreme differences in the delivery techniques which work best 
for each in vitro.  In addition, there are also other limitations associated with the use of newer 
generation modifications, concerning solubility, uptake issues and, most significantly, their 
inability to induce RNase H activity and thus reliance on inhibiting translation via steric 
hindrance. Specifically, it has been shown that morpholinos must be specifically targeted to a 
region within 25 bases of the 5’ cap, i.e. prior to the initiation complex, of a target mRNA to 
effectively reduce gene expression, unlike PS ODNs which work via RNase H mechanisms and 
can affect entire gene transcripts (Summerton, Stein, et al., 1997; Summerton, 1999).  Despite 
their inability to induce the RNase H mechanism, evidence of their superior target specificity and 
total resistance to nuclease digestion, as referenced above, make morpholino ODNs an attractive 
alternative to PS ODNs as their use in antisense research has become increasingly economically 
feasible and alternative methods to scrape-loading cell delivery due to, the development of 
compatible transfection lipids, have emerged (Takei, Kadomatsu, et al., 2005; Morcos, 2001).   
     Locked nucleic acids (LNAs) ODNs are another class of third-generation analogues that have 
gained recent popularity.  LNAs incorporate ribonucleotide bridges into phosphodiester or 
phosphorothioate ODNs to promote greater resistance to nuclease degradation.  LNAs have high 
target affinity, good cellular uptake, and are known to activate RNase H (Orum, Wolter, et al. 
2003; Kurreck, Wyszko, et al., 2002).  Studies involving the specific comparison of 20-mer LNA 
ODNs against a 20-mer phosphorothioate ODN to Intracellular Adhesion Molecule-1 (ICAM-1), 
ISIS 2302, in human umbilical vein endothelial cells (HUVECs) showed that the LNAs were as 
effective in inducing RNase H activity and target mRNA degradation as ISIS 2302 (Obika, 
Hemamayi, et al., 2001). 
    Another antisense modality that has had more notable focus and generated a great deal of 
excitement in recent years is RNA interference (RNAi), a wholly RNA-based antisense 
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mechanism discovered by Fire and colleagues (Fire, Xu, et al., 1998).  The RNAi mechanism 
involves long double-stranded RNA (dsRNA) which is intracellulary processed into small 
interfering RNA (siRNA) by the dicer enzyme.  siRNAs then induce gene silencing through the 
stimulation of RNA-induced silencing complex (RISC) mRNA degradation (Hammond, 
Berstein, et al., 2000).  Just as the DNA-RNA antisense hybrid induces RNase H degradation of 
target mRNA, so does the RISC complex recognize the double-stranded RNA molecule and 
selectively degrade the target mRNA and free the antisense siRNA to bind another target 
(Tomari, Zamore, 2006).  Similar to DNA antisense modifications, chemical modifications to 
RNA nucleotides, such as 2’-O-methyl groups, can increase the duration of siRNA antisense 
activity (Amarzguioui, Holen, et al., 2003).  One of the major advantages to siRNA is that the 
inhibitive effects may be more potent and longer lasting than the short-term range of effects seen 
with AS ODNs.  However, AS ODN effects are more immediate whereas siRNA has a longer 
refractory period, a characteristic supported by the results of RNAi/AS ODN GFP knockdown 
comparison studies done in HeLa cells (Bertrand, Pottier, et al., 2002).   
      Comparisons between LNAs, siRNAs and PS ODNs determined siRNAs to be the most 
effective inhibitor of gene expression, but confirmed that PS ODNs and LNAs are less 
expensive, easier to handle, and have much greater stability in cell culture, compared to siRNAs 
which have a half life of <2 hours in HeLa cells (Grunweller, Wyszko, et al., 2003).  Similiarly, 
comparative studies of siRNA and 2’-O-mehyoxyethyl modified PS ODNs targeting human 
Intracellular Adhesion Molecule-1 (ICAM-1) suggest that siRNA and AS ODN mechanisms 
may have comparable potencies, specificities, and duration of effects therefore demonstrating 
that, while RNAi has generated a lot of excitement, AS ODNs are still one of the leading forms 
of genetic therapy (Vickers, Koo, et al., 2003).  
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     Although backbone modifications have improved the long-term impact of AS ODNs on gene 
expression, rapid nuclease digestion is not the only factor limiting intracellular effects.  An in-
depth study modeling the effectiveness of antisense ODNs indicated that ODN activity is also 
highly dependent upon the rate at which mRNA hybridization occurs as well as on the ability of 
the ODN to prevent or escape entrapment in endosomes (Roth, 2005).  Subtle alterations to 
antisense ODNs could affect their response kinetics and hybridization abilities. Once 
internalized, ODNs are frequently held up in internal vesicles such as lysosomes, endosomes, 
and the endoplasmic reticulum before they make their way into the cytoplasm where they take 
effect (Akhtar, Hughes, et al., 2000).  In addition, studies involving T-lymphocytes showed that 
many mRNAs, though CD54 was not specifically studied, that are involved in immunological 
and inflammatory responses have very short half-lives and thus do not provide a large window of 
opportunity for hybridization to occur (Raghavan, Ogilvie, et al., 2002).   Therefore, for 
antisense ODNs to impart any influence towards the suppression of these rapidly expressed 
genes, the ODN must have a very rapid hybridization rate and its activity can not be impeded by 
entrapment and compartmentalization.   
Antisense Delivery Techniques 
    While backbone modifications have increased the long-term effects and potency of antisense 
technologies, the transport of the polyanionic ODNs through the phospholipid membrane into the 
cell is another problem that must be addressed. Although it is possible that small ODNs may 
have the ability to find cationic regions on the cell membrane and enter via endocytosis, the 
efficiency of uptake is low when compared to delivery efficiencies and cellular accumulation 
achieved through the use of carriers (Nakai, Seita, et al., 1996; Roth, 2005).  In addition, if they 
are internalized, many of these therapeutics are susceptible to degradation by intracellular  
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nucleases or incarceration in lysosomes and endosomes (Hughes, Hussain, et al., 2001; Akhtar, 
Juliano, 1992).  Therefore, the successful implementation of antisense therapies requires a 
delivery vehicle which can improve cellular uptake and transfection efficiency.   
    Oligonucleotide delivery typically consists of carrier-mediated techniques involving 
conjugation to cationic lipids, polymers, proteins, and other hydrophobic constructs to facilitate 
ODN transport into the cell.  Cationic lipids form lipoplexes with nucleic acids that promote 
cellular internalization through electrostatic interactions with ODNs that cause ODNs to become 
encircled in an aqueous layer surrounded by a cationic bilayer that can associate with the 
negatively-charged cell membrane (Hughes, Astriab, et al., 2000).  Lipoplexes such as 
dioelylphosphatidylehanolamine (DOPE) are commercially available in variety of different 
formulations and may also facilitate the release of ODNs entrapped in endosomal and lysosomal 
compartments through membrane disruption (Akhtar, Hughes, et al., 2000).  The advantage of 
lipid systems is that they are known to be biocompatible as they are relatively safe and 
nonimmunogenic (Bartsch, Weeke-Klimp, et al., 2005; Akhtar, Hughes, et al., 2000). Recent 
works have shown the successful in vivo delivery of Intercellular Adhesion Molecuel-1 (ICAM-
1) antisense ODNs to endothelial cells through conjugation with Stabilized Antisense Lipid 
Particles (SALPs) which can be targeted to specific receptor sites using a combination of lipids 
(Bartsch, Weeke-Klimp, et al., 2005).  Unfortunately, while this study demonstrated precise 
delivery of antisense ODNs to target cells, they were unable to achieve target gene inhibition of 
human ICAM-1.   
     This introduces one of the main limitations with conjugation techniques, which is that they 
rely on surface recognition receptors to achieve targeted delivery (Akhtar, Hughes, et al., 2000).  
As in the aforementioned case, not only is this method unreliable, but in antisense therapies, this  
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can introduce another complication in that both healthy and target cells express the specific  
ligand and thus both cell types would receive treatment.  In addition, unique ligands must be 
determined for each targeting application.  Therefore, receptor-ligand interactions as a means of 
achieving targeted antisense drug delivery are insufficient to achieve both spatial and temporal 
control of antisense effects.  These issues exist in reference to a variety of ligand conjugates, 
including cholesterol, glycoproteins, and antibodies that have been used for targeting where 
many of these conjugates were shown to be unique to specific receptors in specific cell systems 
(reviewed in Roth, 2005).   
Antisense Limitations 
   Despite the enormous potential of antisense therapeutics, employment of these strategies in 
vivo has encountered several problems concerning AS ODN biological stability, toxicity, cellular 
uptake, and targeted delivery issues.  Even with improvements to the biological stability of many 
classes of AS ODNs, drug development is still limited by insufficient delivery of gene-based 
therapeutics, targeted delivery issues, and ineffective intracellular distribution even after 
successful transfection is achieved. Different carriers such as cationic lipoplexes have resulted in 
improved delivery of antisense molecules, but non-specific delivery to cells and tissues outside 
of the targeted area have resulted in high background signals in ODN tracking and imaging 
studies (Zhang, Rusckowski, et al., 2001).  This high background signal corresponds to high 
levels of non-specific accumulations of antisense drugs in healthy tissue.  In order to avoid 
potentially harmful effects, a delivery methods needs to be developed that can provide precise 
and accurate control over the spatiotemporal effects of antisense therapeutics.  One possible 
means to target antisense activity is to chemically inactivate antisense ODNs, deliver these 
inactive species systemically, and re-activate them at select sites with light exposure, which can 
be easily controlled. 
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Photosensitive Cage Compounds 
     The chemical inactivation scheme proposed in these studies employs cage compounds which 
are essentially photoremovable protecting groups.  These photoremovable protecting groups are 
chemical species that can be covalently attached to a target molecule via a photolabile bond 
(Kaplan, Forbush, et al., 1978).  The biological application of cage technology is that these 
protecting groups suppress the biochemical function when associated with the target molecule.  
These cage species are designed to respond to a specific wavelength of light such that, upon 
irradiation, the cage group is released and the biomolecule is liberated and its biological activity 
restored (McCray, Trentham, 1989).  Cage groups are generally responsive to wavelengths in the 
300-380 nm range of light (Bernardinelli, Haeberli, et al., 2005).    Light in this range will have 
little effect on the attached biomolecule or on the chemical structure as a whole other than the 
photoreacting species.  Desired cage characteristics include a high extinction coefficient, 
corresponding to strong light absorption characteristics, as well as a high quantum yield, which 
dictates energy conversion efficiency.  Like the antisense agents they are caging, the cage 
compounds must be water-soluble and both the cage and its byproducts should be biologically 
inert.  
     Initial studies demonstrating cage attachment to biomolecules involved the use of a 
nitrobenzyl derivative, 1-(2-nitrophenyl) ethyl (NPE), to inactivate ATP and subsequently 
 photorelease the ATP to its bioactive form by exposure to 340 nm light (Kaplan, Forbush, et al., 
1978).  Although these nitrobenzyl groups were the first and remain a very popular class of cage 
compounds, the number and variety of available cage groups that exhibit control of bioactivity is 
expanding such that researchers are afforded more options in choosing cage group 
characteristics. Since the work by Kaplan et al, several different cage groups have demonstrated 
similar success in the inactivation and photoreactivation of ATP, as seen in Figure 1.2 where a 
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dimethoxylated nitrobenzyl group responsive to 365 nm light was used.  These acetomethylated 
versions of nitrobenzyl groups are employed more frequently in cellular studies due to the 
increased cell permeability of the molecule and lessened biological effects of 365 nm light 
compared to shorter wavelengths.   
 
  
    These nitrobenzyl derived groups remain popular as other commonly used cage groups 
respond to light in the UVB range (290-320 nm) which may cause more direct cellular damage 
than UVA light (320-400 nm) (McCray, Trentham, 1989).  The specific nitrobenzyl derivative 
used in these studies, 1-(4,5-dimethoxy-2-nitrophenyl) ethyl ester (DMNPE) is known to 
specifically absorb light at 355 nm and, as shown in Figure 1.3, based on known adduction sites 
on other biomolecules, the theorized attachment site for DMNPE on nucleic acids is the 
phosphate backbone of the DNA molecule (Walker, Reid, et al., 1988).  Since these studies, 
significant progress has been made towards achieving site-specific attachment of cage groups to 
areas other than the phosphate groups.  Caging of specific bases in various nucleic acid 
analogues has been accomplished with cage attachment to adenosine in DNAzymes and to 
thymidine bases in both phosphoramidites and aptamers (Chaulk, MacMillan, 1998; Heckel, 
Mayer, 2005; Mayer, Heckel, 2006). 
     Applications of cage groups have expanded beyond their beginnings in organic synthesis to 
include to play important roles in the inactivation of various proteins, muscle fibers, 
 
 
 
 
Figure 1.2. Photolysis of DMNPE-Caged ATP 
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neurotransmitters, elementary regulatory molecules such as Ca2+, fluorophores, lipids, and, most 
recently, nucleic acids (Cohen, Stoddard, et al., 1997; Aarhus, Gee, et al., 1995; Schworer, Wirz, 
2001).  The caging of DNA to block genetic activity has demonstrated use in the inactivation of 
Green Fluorescent Protein (GFP) plasmids using DMNPE (Monroe, McQuain, et al., 1999).  
Subsequent studies have expanded the ability of DMNPE to cage nucleic acids as demonstrated  
 
        
             
 
in the reversible control of the hybridization ability of DNA oligonucleotides and the ability to 
cage siRNA  (Ghosn, Haselton, et al., 2005; Shah, Rangarajan, et al., 2005).  However, the use of 
nitrobenzyl groups is limited by concern about possible cytotoxic byproducts of photolysis 
reactions, such as the formation of nitrosobenzaldehyde (DMNBB) or nitrosoketone (DMNPE), 
leading to the development of other photoprotective groups. 
    There are a great variety of photoprotecting cage groups that have been developed outside of 
the nitrobenzyl family.  One example is the brominated 7-hydroxycoumarin-4-methyl (Bhc) 
cage.  Bhc groups have achieved success in the caging of carboxylic acids and may offer the 
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advantage of having photosensitivity in the infrared wavelength range using two-photon 
excitation (TPE) (Furuta, Wang, et al., 1999; Banjeree, 2003).  TPE occurs when two long-
wavelength photons are simultaneously (10 -16 s) absorbed by a fluorescent molecule.  This 
allows for the use of low-energy wavelengths like IR, which are capable of deeper tissue 
penetration and minimized photobleaching affects (Denk, Strickler, et al., 1990; Diaspro, 
Robello, 2000). The advantage of two-photon excitation is the decreased time of cell culture 
irradiation due to dual photon energy absorption.  However, there is minimal evidence to support 
the theory that a protective group that has very low quantum efficiency in the UV range is going 
to react with higher quantum energy in the IR range through the use of the two-photon system.  
In a study by Zhao et al, they presented the first example of the photolysis of a a 1-(2-
nitrophenyl)ethyl (NPE) cage group with infrared light via a TPE system (Zhao, Zheng, et al., 
2004).  The NPE group was associated with a coumarin molecule was shown to have 
surprisingly high photolysis efficiency at 365 nm, a phenomena that was enhanced through the 
implementation of a TPE system with 740 nm light (Zhao, Zheng, et al., 2004).  Photolysis 
efficiency was measured as a product of the quantum yield and the extinction coefficient of a 
cage molecule at a specific wavelength.   However, the use of this group was specifically 
intended for use with a fluorescent coumarin substrate for in vivo imaging applications as 
compared to the NDBF and Bhc caged groups which have potential applicability to other 
biomolecules (Zhao, Zheng, et al., 2004; Momotake, Lindegger, et al., 2006; Furuta, Wang, et 
al., 1999). 
     Denk et al were able to conclude that photorelease of ATP from the DMNPE caged form is 
much faster and can be accomplished in smaller volumes using TPE (Denk, Strickler, et al., 
1990).  However, the aforementioned Bhc groups have slower release kinetics and are still used 
in single-photon excitation with quantum yields similar to that achieved with DMNPE (Banjeree, 
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2003).  One of the most recent cage groups to be developed is a nitrodeibenzofuran (NDBF) 
group that has been shown to be up to 160x more efficient in photolysis than other nitrobenzyl-
derived cages (Momotake, Lindegger, et al., 2006).  The NDBF group has demonstrated 
quantum yields of up to 0.7 and extinction coefficients of 18,400 M -1cm-1 when reacted with 
Ca2+ and has the ability to undergo two-photon excitation at 350 nm.  This can be compared to 
the extinction coefficient of 4795 M -1cm-1 reported for DMNPE nucleic acid studies (Ghosn, 
Haselton, et al., 2005).  The advantage of having two-photon excitation capabilities is that less 
energy per photon is needed to photocleave the protecting group, therefore is a decreased risk of 
cellular damage as demonstrated with the NDBF cage which has confirmed compatibility with 
cell systems and shows promise for in vivo applications (Momotake, Lindegger, et al., 2006).    
     In addition, advances in solid-phase ODN synthesis have enabled individually caged 
nucleotides to be incorporated into oligonucleotides and have proven to be compatible with 
fluorophore-quencher conjugation allowing for real-time monitoring of cage release (Tang, 
2005).  This innovative caged fluorescent oligodeoxynucleotide consists of a fluorophore 
adjoined to a DABSYL quencher and a PC linker which responds to 365 nm light.  Results of 
these studies show a 95% release of active biomolecule based upon fluorscein response alone 
and, if conjoined with in vitro studies to demonstrate restoration of biomolecule activity, could 
be used to offer additional support of the efficacy of antisense treatments. 
     The success achieved in these studies indicates that the employment of photoremovable cages 
may provide a means of achieving spatial and temporal control of biofunctionality.  Caged 
molecules can be delivered systemically throughout a biological system in a bioinactive form.  
Spatio-temporal control of activity can subsequently be elicited through the photoexposure of 
targeted cells and tissues.   For example, UVA light has been used to achieve targeted retinal 
intravascular photoactivation of thrombin from a methylcinnamate cage (Arroyo, Jones, et al., 
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1997 ).   As previously mentioned, one of the important characteristics of these cages is that they 
have high energy conversion efficiencies in order to limit cellular exposure to damaging UV 
light. Newer cage groups have received more significant interest due to reportedly improved 
photochemical characteristics compared to characteristics of DMNPE-ATP (Wooton, 1989).  
However, more recent experiments involving caged NAD, NADP and the antibiotic doxycycline 
have indicated that DMNPE release rates and product formation may have better photochemical 
characteristics than what was once thought, indicating that these characteristics may simply be 
dependent upon the moiety being caged (Cohen, Stoddard, et al., 1997; Cambridge, Geissler, et 
al., 2006).  Experiments with NAD and NADP were able to achieve photolysis rates of 1.7E 104 
– 1.8E104 (s-1) and quantum yields of 0.17 and 0.19, values almost twice that of which could be 
achieved with α-Carboxy-2-nitrobenzyl (CNB) group (Cohen, Stoddard, et al., 1997).  Similarly, 
DMNPE-caged doxycycline achieved yields of 0.013-0.075 with no reported measurements of 
release rates (Cambridge, Geissler, et al., 2006).  Interestingly, in this experiment, the reaction of 
DMNPE with doxycycline produced two different stable diasteromers of the caged product, only 
one of which demonstrated acceptable suppression of genetic activity.  Reactivation was 
subsequently achieved upon exposure to UV light in the 300-400 nm range.  
Limitations to Caging 
     It has been noted that DMNPE-caged nucleotides may be prone to hydrolysis and thus result 
in a caged-product that has residual native ODNs in solution (Wootton, Trentham, 1989).  In 
order to avoid the resulting system “leaks” where some ODNs retain their hybridization ability, 
complete ODN inactivation require the attachment of a minimum number of cage groups.  
However, excessively caged ODNs may require large doses of light and make achieving any 
degree of photo-restoration difficult.  This effect was demonstrated when DMNPE-caged 
plasmids were transfected into HeLa cells and exposure to UV light resulted in only partial 
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restoration of bioactivity (Monroe, McQuain, et al., 1999).  Limiting the amount of the DMNPE 
group that is added to the ODN solution restricts the number of cage groups bound to each 
individual ODN.  While this is advantageous to achieving successful photocleavage, the 
disadvantage is that a number of the ODNs in the solution may have only few cage groups 
attached and may still be able to hybridize.  This contributes to the system leak with 
hybridization occurring in the uninduced state.  In order to fully optimize the use of cage 
compounds to both inactivate and subsequently reactivate biomolecules upon light exposure, 
excess cage and non-caged samples are removed from the reaction products.   
    The other main limitation to the use of cage compounds is that cellular exposure to UV light is 
known to induce cytotoxic effects over long periods.  A potential solution to this problem would 
be to use cage groups that are photoresponsive to longer, less damaging wavelengths.  However, 
cage groups, such as nitroindolines and the phenacyl group, that are known to be responsive in 
the visible region have slow release kinetics, in the magnitude of minutes and many are not water 
soluble (Shembeckar, 2005; Banerjee, Grewer, et al., 2003).  Therefore, the majority of cage 
groups used in biological applications respond to UV light.  UV responsive groups that have 
sufficiently high quantum yields have been shown to be photolyzed with light in the 
infrared/visible wavelength range using two-photon excitation (Fedoryak, Dore, 2002; Zhao, 
Zheng, et al., 2004; Furuta, Wang, et al., 1999; Momotake, Lindegger, et al., 2006).   
Antisense in Action: Targeting Crohn’s Disease 
     Antisense strategies have obvious applications in the targeting of mutated genes and disease 
causing proteins.  However, another area of potential importance for antisense therapy is in the 
suppression of immune responses.  Transplantations, autoimmune diseases, and chronic 
inflammation involve the induction of a normal cascade of events within the immune system.  
Vitravene (formivirsen sodium) is an 21-mer phosphorothioate antisense therapeutic developed 
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by ISIS pharmaceuticals for the treatment of cytomegalovirus retinitis, characterized by retinal 
inflammation, and is the first and only antisense drug to have received FDA approval in the 
United States (de Smet, Meenken, et al., 1999; Crooke, 1998)  As of 2005, there were five other 
oligonucleotide antisense therapeutics involved in phase 3 clinical trials and expecting FDA 
approval (Patil, Rhodes, et al., 2005).   
  
 
 
 
 
 
 
 
     Of these antisense drugs awaiting FDA approval, only one is indicated for the treatment of a 
non-cancer condition. Alicaforsen (ISIS 2302) is the first antisense agent to be targeted to a 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4. ISIS 2302 Antisense Mechanism of Action Against ICAM-1 
Cationic lipid conjugation facilitates ICAM-1 asODN cellular entry.  
Inside the cell, phosphorothioate modifications help protect the asODN 
from nuclease digestions. The asODN is specifically targeted to ICAM-1 
mRNA, which it binds to by shuttling between the cytoplasm and nucleus 
resulting in target degradation by the RNase H enzyme and reduction of 
ICAM-1 protein expression on the cell surface. 
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gastrointenstinal disease (Caprilli, Viscido, et al., 2002).  ISIS 2302 is a 20-mer phosphorothioate 
antisense oligodeoxynucleotide complementary to ICAM-1 and designed to treat Crohn’s 
Disease (Figure 1.4).   Crohn’s is an inflammatory condition characterized by persistent 
leukocyte presence in gastrointestinal tissue (Yacyshyn, Barish, et al., 2002).   Leukocyte 
recruitment to tissue is the result of a cascade of immunological events.  Though the trigger for 
this cascade is unclear, there are a variety of cytokines and intercellular adhesion molecules 
involved in the process that can be targeted with antisense molecules. In particular, the disease is 
characterized by a marked increase in intercellular adhesion molecule-1 (ICAM-1/CD 54) 
expression on the surfaces of cells in the ileum, colon, and peripheral blood local to the intestinal 
area.  ICAM-1 is a transmembrane cell surface protein that is a member of the immunoglobulin 
superfamily whose up-regulation is cytokine inducible (Chiang, Chan, et al., 1991). This 
inducible expression is mediated by several different proinflammatory cytokines in a number of 
different cell types (Dustin, Rothlein, et al., 1986; Nedbal, Cho-Chung, 2002; Lucas, Van 
Rompaey, et al., 2004).  Interferon-gamma (IFNγ) is a particularly potent moderator of ICAM-1 
expression which will be used in these experiments to up-regulate gene expression.  Once 
introduced to the cell, IFNγ activates the Janus Kinases (JAK)-signal transducers and activators 
of transcription (STAT) pathways leading to the interferon response element (IRE) located 100 
base pairs away from the ICAM-1 promoter site (Roebuck, Finnegan, 1999).  ICAM-1 up-
regulation results in increased leukocyte migration from the vasculature to inflamed tissue sites 
and is correlated to increased activity of Crohns’s disease (Yacyshyn, Chey, et al., 2002). 
     ISIS 2302 is a documented substrate for RNase H (Lebedeva, Stein, 2001; Walder, Walder, 
1988).  A study to determine the pharmacokinetics and effectiveness of ISIS 2302 in the 
treatment of Crohn’s, results confirmed that ISIS 2302 suppresses cytokine-inducible up-
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regulation of ICAM therefore resulting in disruption of the immune cascade and inflammation 
reduction (Yacyshyn, Chey, et al., 2002).   
Project Aims 
     The hypothesis of this study was that the inactivation of antisense ODNs through the covalent 
attachment of a caged compound can be reversed with exposure to near-UV light in vitro to 
restore bioactivity through the optimization of two parameters: (1) minimization the number of 
attached cage groups required for antisense inactivation and (2) subsequent minimization of 
cytotoxicity due to photoexposure. The specific objectives of this project were to assess caging 
efficiencies through absorbance spectrophotometry and gel electrophoresis to determine degrees 
of cage-inactivation of ODN products.  We also proposed to evaluate the affect of cage 
attachment on hybridization activity using molecular beacon based assays and experimental 
modeling. Additional objectives of this project were to evaluate the effects of other experimental 
conditions, including UVA light and transfection lipids, on cell systems.  Light-dose responses of 
inducible ICAM-1 expression in HeLa cell cultures were studied in order to determine how 
successful photoactivation of caged PS AS ODNs could be achieved with minimal affect of cell 
culture.  In meeting this objective we will show that cage techniques can be utilized as a means 
of achieving spatial and temporal control of antisense activity.  Overall, we will demonstrate the 
ability to use engineering principles to overcome the inherent challenges in achieving specific 
and controlled effects in cell and tissue systems. 
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CHAPTER II 
 
IN VITRO CONTROL OF ANTISENSE ACTIVITY USING CAGED 
PHOSPHOROTHIOATE OLIGODEOXYNUCLEOTIDES 
 
 
Introduction 
 
 There is great potential in the use of oligonucleotide (ON) antisense agents in the 
treatment of various diseases and genetic disorders.  Antisense agents are synthesized short, 
single-stranded RNA or DNA nucleotide sequences that are complementary to target mRNA or 
DNA sequences.  Hybridization of antisense drugs to their targets in the nucleus and/or 
cytoplasm results in translation inhibition. There are a number of different classes of antisense 
agents which have different chemical modifications that work through either enzymatic or steric 
mechanisms to result in target gene inhibition.  It was once believed that compounds that worked 
via enzymatic RNase H mechanims were the most potent; however there is increasing evidence 
that some of the newer generation antisense ODNs which work through steric hinderance are 
equally potent (Grunweller, Wyszko, et al., 2003; Kurreck, Wyszko, et al., 2002).  First 
generation structural modifications, such as phosphorothioate oligodeoxynucleotides (PS-
ODNs), which have sulfur-substituted linkages, induce RNase H whereas other second and third 
generation modifications such as phosphoramidates, phosphorodiamidate morpholinos, and 
peptide nucleic acids (PNAs) do not (Wu, Lima, et al., 2004; Summerton, 1999; Gray, Basu, et 
al., 1997).  More recent analogues such as locked nucleic acids (LNAs) and small interfering 
RNAs (siRNAs) have received attention due to their high efficacy (Obika, Hemamayi, et al., 
2001; Fire, Xu, et al., 1998).  Comparisons between LNAs, siRNAs and PS-ODNs found 
siRNAs to be the most effective inhibitor of gene expression, but confirmed that PS-ODNs and 
LNAs are less expensive, easier to handle, and have much greater stability in cell culture  
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compared to siRNAs, which have a half life of less than 2 hours in HeLa cells (Grunweller, 
Wyszko, et al., 2003).  Similarly, comparative studies of siRNA and 2’-O-mehyoxyethyl 
modified PS-ODNs targeting human Intracellular Adhesion Molecule-1 (ICAM-1) suggest that 
siRNA and AS-ODN mechanisms may have comparable potencies, specificities, and duration of 
effects, therefore demonstrating that while RNAi has generated a lot of excitement, AS-ODNs 
are still a viable form of genetic therapy (Vickers, Koo, et al., 2003).  
      Although there have been many advancements made in their design and synthesis, antisense 
therapeutics represent a less mature technology than small molecule pharmaceuticals. ISIS 
Pharmaceutical’s cytomegalovirus prodrug, Vitravene, a second-generation phosphorothioate 
ODN, is currently the only antisense drug with full FDA approval.  Currently, a challenge to the 
in vivo implementation of these techniques is the ability to control antisense activity, a problem 
which could be overcome through targeted delivery to limit effects to cells and tissues of interest. 
Common delivery techniques allow for receptor mediator targeting and have applications to 
specific systems but may not work well outside of in vitro applications due to issues with 
simultaneous effects in healthy and targeted cells.  In order to limit antisense activity to specific 
cell types in specific tissues or organs of interest, more precise targeting strategies have been 
introduced which allow for the delivery of inactivated transgenes whose  activity can be site-
specifically induced.   
     One such means of targeting antisense agents is through the control of hybridization. 
Photoremovable protecting groups are chemical species that can be covalently attached to a 
biomolecule via a photolabile bond and be used to suppress biochemical function (Kaplan, 
Forbush, et al., 1978).  These photocleavable “caged” species are designed to respond to a 
specific wavelength of light such that, upon irradiation, the cage group is released and the  
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biomolecule is liberated and its biological activity restored (McCray, Trentham, 1989).  Caged 
compounds are generally responsive to wavelengths in the 300-380 nm range of light 
(Bernardinelli, 2005).  Initial studies demonstrating the caging of biomolecules involved the use 
of a nitrobenzyl derivative, 1-(2-nitrophenyl) ethyl (NPE), to inactivate ATP and subsequently 
photorelease the ATP to its bioactive form by exposure to 340 nm light (Kaplan, Forbush, et al., 
1978).  More recently, a similar nitrobenzyl derivitive, 1-(4,5-dimethoxy-2-
nitrophenyl)diazoethane (DMNPE), has been used to block genetic expression of plasmid DNA 
(Monroe, McQuain, et al., 1999).  Subsequent studies employed DMNPE in the cage inactivation 
of nucleic acids as demonstrated in the reversible control of the hybridization ability of DNA 
oligonucleotides and the ability to cage siRNAs  (Ghosn, Haselton, et al., 2005; Shah, 
Rangarajan, et al., 2005).  
     Extending the application of caging chemistries to DNA ODNs with modified backbones 
offers the potential of targeted control of antisense drug activity.  This work demonstrates the 
inhibition of antisense activity and the use of UVA light to restore its effects in cell culture. ISIS 
2302 is a 20-mer phosphorothioate antisense oligodeoxynucleotide complementary to the 3’ 
untranslated region (UTR) of intercellular adhesion molecule-1 (ICAM-1/CD 54). Studies 
evaluating the pharmacokinetics and effectiveness of ISIS 2302 have confirmed its ability to 
suppress cytokine-inducible up-regulation of ICAM-1 in vitro (Yacyshyn, Barish, et al., 2002) 
presumably through RNase H mechanisms (Stein, 2001; Walder, Walder, 1988).   The influence 
of the photocaging compound DMNPE on hybridization of ISIS 2302, a 20-mer PS ODN, was 
modeled using a molecular beacon assay.  Based on this model, a relationship between the 
number of attached cage groups and the inactivation of hybridization activity was established.  In 
addition, the light-dose effects on cell morphology and ICAM-1 target protein expression were  
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studied to determine that 40 J/cm2 of UVA light was the maximum dose that could be used for 
photorestoration of antisense activity in cell based studies.  Caged ISIS 2302 activity was 
controlled in HeLa cell cultures using this light and resulting ICAM-1 expression was measured 
by flow cytometry. 
Materials and Methods 
ODN Caging and Purification 
  The PS ODN used was ISIS 2302, 5’-GCCCAAGCTGGCATCCGTCA-3’ (IDT, 
Coralville, IA). PS ODN caging methods were adapted from previous studies by Ghosn et al. 
(Ghosn, Haselton, et al., 2005).  To activate the cage compound, 5 mg of 1-(4,5-dimethoxy-2-
nitrophenol) hydrazone (Molecular Probes, Invitrogen, Carlsbad, CA) was allowed to mix with 
50 mg of manganese (IV) dioxide in 1 ml of dimethylforamaide (DMF) at 25 °C for 20 minutes.  
The MnO2 was then filtered out using 100 mg of Celite supported by glass wool in a 1 cc 
tuberculin syringe.  Activated cage, 50, 100 or 150 µl, was then mixed with 200 µg of PS-ODN 
in 80 µl of 50 mM Bis-Tris (pH 5.5), 120 µl water, and 50 µl DMF and agitated for 24 hours at 4 
°C. Reactions were then removed from the agitator and microfuged for 30 seconds.  A bed of 
1500 µl of a 33% (v/v) DMF LH-20 Sephadex slurry (GE Healthcare, Piscataway, NJ) was 
packed into a Mini Quick Spin column (Roche Diagnostics, Indianapolis, IN) through 
centrifugation at 1000 x g, for 5 minutes (MiniSpin, Eppendorf, Westbury, NY).  Excess cage 
unassociated with PS-ODN was removed by filtering the 600 µl reaction volume through the 
Sephadex column by spinning the column (1000 x g, 5 mintues).  The caged product was then 
further purified through the use of Microcon YM-3 (3000 molecular weight cut-off) filters 
(Millipore, Bilerica, MA).  Reactions were spun at 12 x 103 x g for 90 minutes, followed by a 
400 µl water wash an additional spin for 120 minutes. Caged ODN was subsequently 
resuspended in 70 µl water and stored at 4 °C, protected from light. 
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Determination of Caging Efficiency 
 In order to quantify the degree of DMNPE attachment, concentrations of native ODN and 
DMNPE-caged ODN were compared through absorbance spectrophotometry.  Samples were 
scanned for absorbance from 230 to 500 nm (ThermoSpectronic Genesys 6, Waltham, MA).  
DNA has a characteristic absorbance at 260 nm and no absorbance above 300 nm.  DMNPE has 
a characteristic 355 nm absorbance.  Based on absorbance values efficiencies were calculated 
using the following formulas adapted from Ghosn et al. (Ghosn, Haselton, et al., 2005): 
                               A260 nm = [(εDNA/260)*(CDNA)*(l)] + [(εDMNPE/260)*(CDMNPE)*(l)]                   (1)              
                                                    A355 nm = [(εDMNPE/355)*(CDMNPE)*(l)]                                       (2) 
Where A260 gives the absorbance at 260 nm; A355 is the absorbance of DMNPE at 355 nm; ε is 
the molar extinction coefficient for each molecule at the specified wavelength; c is the 
concentration of the solution; l is the path length of the cuvette (1 cm) and 19 is the total number 
of phosphate groups in the ODN.  Based on concentrations of DMNPE and DNA in each sample, 
caging efficiencies were determined using the following equation: 
                                             Cageefficiency = [(CDMNPE ÷ CDNA) ÷ 19] * 100                                   (3) 
Photoactivation and Fluoresence Hybridization Studies of Caged ODNs 
In order to determine light doses necessary to release caged-ODNs,  0.5 µg native or caged 
ODNs were exposed to 365 nm light for increasing durations of time.  The UVA light source 
used in these studies has a peak output at 365 nm and a fluence rate of 0.665 W/cm2 at 4.2 cm 
(GreenSpot, American Ultraviolet, Lebannon, IN) when used in conjunction with short bandpass 
(SWP-2502U-400; Lambda Research Optics, CA; diameter 25.4mm; 1.5mm thick) and IR (KG-
2; Lambda Research Optics, CA; 50.8mm square, 2mm thick) filters.  Following light exposure, 
ODNs were mixed with a molecular beacon, Molecular Beacon-1 (MB1; Biosearch 
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Technologies, Novato, CA) that was specifically designed to hybridize to ISIS 2302 (Monroe, 
2005).  The sequence of MB1 is 5’-FAM-gtgcgTGACGGATGCCAGCTTGGGCcgcac-BHQ1-
3’ where capital letters represent the bases complementary to ISIS 2302, lowercase letters 
represent the self-complimenting bases forming the stem of the beacon structure, and the 
underlined sections represent the fluorophore ([3’,6’-dipivaloylfluoresceinyl)-6-
carboxamidohexyl]-1-O-(2-cyanoethyl)-(N,N-diisopropyl)phosphoroamidite (FAM)) and 
quencher (Black Hole Quencher-1). Hybridization studies were done by mixing 450 ng of native, 
caged, or caged-flashed ODN and 150 ng of MB1  (3:1 ODN:MB1 ratio) in 50 mM NaCl, 1 mM 
EDTA (pH 7.0).  Hybridization mixtures were denatured at 95 °C for 5 minutes and slowly 
cooled over 20 minutes to a final temperature of 25 °C (iCycler, BioRad, Hercules, CA) .  
Fluorescent analysis was carried out by exciting hybridization mixtures (100 µl) at 492 nm and 
detecting emission at 515 nm using a LS55B Luminescence Spectrophotometer (Perkin Elmer, 
Boston, MA).   
  
 
Gel Electrophoresis: Comparison of Caging Among Different ODN Variations 
     Native, caged, and cage-flashed 20-mer ODN were compared by gel electrophoresis.   Two 
phosphorothioate variations were used to demonstrate cage and cage-release effects on ODN 
mobility: fully thioate linked and 5’-3’-end thioate linked.  The ODNs were run on a 15% 
polyacrylamide non-denaturing gel in tris-borate (TBE) buffer (100 mM tris-borate; 2 mM 
Figure 2.1. Molecular beacon hybridization assay 
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EDTA; pH 8) at 70 V for 105 minutes. Gels were then stained with 1X SYBR-Gold nucleic acid 
gel stain (Molecular Probes, Eugene, OR) in TBE buffer for 20 minutes. 
Cells and Culture Conditions 
 Human epithelial carcinoma (HeLa) cells were maintained in Dulbecco’s modified 
Eagle’s reduced serum medium (DMEM-RS) supplemented with 3% fetal bovine serum (FBS) 
(Hyclone, Thermo Scientific, Logan, UT).  Cells were grown at 37° C in a 5% CO2 humidified 
atmosphere and routinely split one to two times a week following trypsinization.   For lipid-
mediated transfection, cells were seeded at a density of 50,000 cells per well on 12-well plates 
(BD Falcon, Franklin Lakes, NJ) and allowed to adhere for 18-24 hours.  Cells were then washed 
1x with pre-warmed (37° C) OptiMEM (Invitrogen, Carlsbad, CA).  For each well, 0.26 µM AS 
ODN was complexed at a 3:1 lipid:DNA ratio with 4.5 µl Oligofectamine transfection reagent 
(Invitrogen, Carlsbad, CA) in 100 µl of OptiMEM for 15 minutes at room temperature. 
Transfections were carried out in a total volume of 0.9 mL OptiMEM.  Cells were incubated for 
5 h at 37 ° C, 5% CO2 after which transfection media was replaced with 0.9 mL fresh OptiMEM 
and appropriate wells were flashed.  Medium was then replaced with 0.9 mL DMEM containing 
3% FBS.   After an additional 4 h incubation 100 U/mL IFNγ was added to appropriate wells to 
stimulate ICAM-1 expression and cells were incubated overnight.  Cells were then trypsinized 
with 0.5 mL of 0.25% trypsin (Hyclone, Logan, UT) for 5 minutes at 37 ° C, 16 h after 
stimulation with IFNγ. 
Quantification of ICAM-1 Expression: Immunofluorescence and Flow Cytometry 
     Cells were washed 1x with CMF-PBS containing 2% Bovine Serum Albumin (BSA) (EBD 
Biosciences, LaJolla, CA).  Cells were then incubated for 30 minutes at room temperature with 5 
µl of a phycoerytherin (PE)-conjugated or 2.5 µl of an Alexa Fluor 488 CD54/ICAM-1 
monoclonal antibody (BD Biosciences, Franklin Lakes, NJ) with 20 µL 2%BSA in CMF-PBS.  
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Cells were then washed 1x with 0.5 mL CMF-PBS and subsequently resuspended in CMF-PBS 
containing 1% paraformaldehyde (pH 7).   
     Data acquisition was performed on a Becton-Dickinson FACScan flow cytometer employing 
a 15mW 488 nm argon-ion laser and 530 nm (FITC) or 585 nm (PE) bandpass filter and 
CellQuest Pro Software.  For each sample, side scatter, forward scatter, and fluorescence data 
(FL2 for 530 nm; FL3 for 585 nm) were collected for 20,000 cell events. Analysis was 
performed using WinList software (Verity Software House, Topsham, ME).  Dead cells were 
gated out using forward versus size scatter dot plot data and the remaining live cell population 
was further gated based on IFNγ negative controls using FL2 vs. FL3 fluorescence dot plots.  
Antisense effects were quantified as number of responsive cells based on the percentages of cells 
in the IFNγ negative control gate.  In addition, ICAM-1 expression was quantified based on the 
linearized mean fluorescence intensity (mFI).  Protein expression levels were standardized using 
the following formula adapted from Nedbal et al (Nedbal, Tomakidi, et al., 2002):  
               Percent Knockdown = [(mFI ASODN+/IFNγ+)-(mFIIFNγ-)] / [(mFI IFNγ+)– (mFIIFNγ-)]          (4) 
UVA Light Effects on ICAM Expression 
     The target gene ICAM-1 is expressed at low basal levels in the absence of any stimulatory 
cytokine.  To validate our system we tested the effects of 365 nm light on both basal level and 
IFNγ-stimulated ICAM-1 protein expression.  Triplicate samples of pre- or post-transfected cells 
were exposed to 10, 20, 40, 80, 120, or 200 J/cm2 of light were performed in.  Cells were 
analyzed for ICAM-1 expression, as described, using flow cytometry. 
Results 
Non-Denaturing Gel Electrophoresis of Caged ODNs 
      In order to compare the effects of both caging and photo-release on the AS ODN, gel 
mobilities were assessed by non-denaturing gel electrophoresis. For two AS ODN variations, 
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fully phosphorothioate modified ODN and 5’3’-end phosphorothioate modified ODN, native, 
caged, and cage-flashed samples were compared. Band intensities are higher for each native 
sample (Figure 2.2; lanes 2, and 5) as compared to the corresponding cage and cage-flashed  
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samples (Figure 2.2; lanes 3, 4 and 6, 7, respectively).  The differences in intensities between 
cage and native samples is not unexpected due to the potential interference of the attached cage 
group in the ability of the SYBR-Gold 
stain to intercalculate between the 
bases.  The limited increase in 
intensity of caged-flashed bands as 
compared to the caged bands 
demonstrates incomplete photo-
removal of the cage groups from the 
ODNs after exposure to 40 J/cm2.  
However, at least a partial 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2.  Non-denaturing gel with 50 ng native, caged, and caged-flashed ODNs 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3. Absorbance spectra of caged and cage-
flashed ODN 
 
 
 
 
Figure 2.3. Absorbance spectra of caged and caged-
flashed ODN 
 33 
photorelease of the ODNs from cage groups is suggested by the characteristic electrophoretic 
mobility shifts corresponding to the changes in DMNPE attachment.  Cage-flashed bands have 
increased mobility over cage bands approaching that of the native sample bands.  Band shifts 
correlate with absorbance spectrophotometry results  (Figure 2.3) which show a significant 
decrease in the 355 nm peak after flashing, resulting in a cage-flashed product whose absorbance 
characteristics also more closely resemble native ODN. 
Fluorescent Measurements of Hybridization Products 
     The fluorescence of MB1 indicates hybridization with its a complementary target.  MB1 
solutions with either native or caged-flashed ODNs resulted in fluorescent measurements that 
were significantly higher than solutions of MB1 alone or of MB1 with caged ODN (Figure 2.4).  
MB1 alone in solution exhibits very little background fluorescence as demonstrated by an 
average reading of 114 ± 2.5 (mean ± SEM, n=3) relative fluorescence units (RFUs).  By 
comparison, when MB1 was mixed with the target ODN, hybridization resulted in readings of 
848 ± 6.2 (n=4) RFUs.    Caged ODNs were also hybridized to MB1 and fluorescence 
measurements were found to be dependent on the number of attached cage groups, but were 
always less than native ODN hybridization mixtures. Three different amounts of cage (1.08mM, 
4.32mM, or 6.48mM) were reacted with ODNs having fully phosphorothioate backbone 
chemistry.  In addition, two different amounts (2.16mM and 6.48mM) were tested in two other 
backbone chemistries, an ODN with three phosphorothioate modifications at each (3’ and 5’) 
end, and an ODN with alternating phosphorothioate and phosphodiester backbone chemistry. In 
order to identify what effect, if any, phosphorothioate chemistry had on cage group attachment 
and release abilities, a comparison was done between the three phosphorothioate chemistries 
with 6.48 mM of DMNPE. The amount of light used to photoactivate the caged effector ODN 
(40 J/cm2) was based on cell light dose tolerance limits (data follows).  Using this light dose  
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Figure 2.4. The effects of different amounts of DMNPE on hybridization 
activity inhibition and photorestoration.  Full phosphorothioate backbone 
chemistries were evaluated for hybridization with a complementary molecular 
beacon at low (1.08mM), medium (4.32mM), and a high (6.48mM) cage 
concentrations.  Other phosphorothioate modifications were initially tested at a 
mid-range (2.16mM) and high (6.48mM) concentrations. Cage-flashed samples 
were dosed with 40 J/cm2 of light.  
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100% photoresoration was not seen in any of the caged samples.  An alternative method would 
have involved increasing light doses until maximum photo-release was achieved.  However, as 
this system was being evaluated for in vitro use, total light doses were set below cellular 
thresholds. The minimum degree of caging needed to block bioactivity was then evaluated so 
that minimal light doses could be used for photoactivation. 
Table 2.1. Relative effects of cage on fluorescence emission and hybridization 
activity between samples.   Sample RFU values represent total RFU with basal 
molecular beacon RFU (114) subtracted out.  Hybridization activity was 
calculated as a percentage of native activity, 848 ± 6.2; n=4 (mean ± SEM) RFUs  
   mM Caging Caged Cage-Flashed 
  Cage Efficiency RFU % Activity RFU % Activity 
1.08 13% 538 63 633 75 
4.32 41% 32 4 295 35 PS 
6.48 82% 0 0 28 3 
2.16 20.8% 312 37 525 62 5'3' Modified PS 
6.48 20.4% 0 0 22 3 
2.16 70% 396 47 656 77 Alternating PS 
Modification 6.48 73% 2 0 75 9 
 
     For all phosphorothioate chemistries tested, reactions that received higher amounts of cage 
compound exhibited lower relative fluorescence, indicating a lower level of hybridization ability.  
For heavily caged (6.48 mM) reactions the addition of 150 µg of DMNPE to 200 µg ODN 
resulted in complete hybridization inactivation.  By comparison, only reacting 25 µg of DMNPE 
with 200 µg ODN (1.08 mM reactions) allowed the ODNs to maintain 63% of their activity.  In 
order to better characterize the relationship between cage presence and hybridization activation, 
we evaluated the relationship between the degree of cage attachment and hybridization 
inactivation in the fully phosphorothioated ODN (Figure 2.5).  This relationship was modeled 
with a sigmoidal dose-response as a function of the number of attached cage groups using 
SigmaPlot 9 software (SYSTAT, San Jose, CA).   
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                                                  y = 97.1 /  (1+ exp ( - ( x – 15.9) / - 4.75 ))                           (5) 
R2 = 0.975 
     Molecular beacon assays allowed for the monitoring of hybridization abilities of ODNs at 
95°C in a thermal cycler.  In order to confirm that antisense ODNs would also hybridize to their 
targets in vitro, a series of molecular beacon hybridization assays were conducted to compare 
activity at 95°C and 37°C.  Various concentrations of ODNs (90-875 ng), as an estimate range of 
in vitro target availability, were mixed with molecular beacon.  Each set of reactions was 
conducted over a 20 minute hybridization period, either in the thermal cyler at 95°C or in the 
Figure 2.5. The relationship between degree of PS ODN caging and the 
blockade of hybridization ability 
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incubator at 37°C.  Hybridization did occur at each temperature, indicating in vitro hybridization 
ability.  Based on these results 450 ng of DNA were used in subsequent hybridization assays. 
 
 
Effects of UVA Light on ICAM-1 Expression in HeLa Cells 
     Determination of the required light to photorelease caged AS ODNs in vitro must also 
account for the ability of the cells to withstand photo-treatment.  To account for experimental 
condition effects on cells, HeLa cell responses to UVA light were measured under control 
(cytokine-stimulated) and experimental (AS transfected) conditions.  Light doses below 40 J/cm2 
had negligible effects on ICAM-1 expression in either controls or antisense transfected cell 
populations.  Doses above 40 J/cm2 resulted in a 42.2 ± 4.7% (mean ± SEM; n=3) decrease in 
ICAM-1 expression in positive controls and a 28.4 ± 2.8% (mean ± SEM; n=3) decrease in 
antisense treated cells (Figure 2.7 (a)).  For all cell experiments, each “n” replicate represents the 
analysis of 20,000 cell events.  In addition to changes in protein expression in response to light 
treatments, morphological changes were also monitored.  Cell morphology remained relatively 
unchanged at doses below 40 J/cm2 but alterations became increasingly evident as light doses  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.6. Hybridization temperature comparison of molecular 
beacon activity 
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(b) 
(a) 
* * 
Figure 2.7. Effects of UVA light on HeLa Cells  (a) Effect of UVA light doses on 
ICAM-1 expression (mean ± SEM) as measured by flow cytometry in cytokine up-
regulated cells in antisense treatments and controls.  Light doses below 40 J/cm2 
were not significantly different (t-test p<0.05; n=3) between controls or between 
antisense treatments. Statistically different treatments are marked with asterisks. (b) 
Cell morphology of controls cells in response to light dose treatments 
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increased (Figure 2.7 (b)).  The 60s (40 J/cm2) dose had little effect on number of attachedc cells 
whereas doses of 180s and 300s resulted in loss of adherent cells.  
Effects of Transfection Lipids on ICAM-1 Expression in HeLa Cells 
     In order to verify that changes in ICAM-1 protein expression were a result of up-regulation 
and knockdown alone and not due to lipid effects, we compared basal and IFNγ-stimulated 
controls with or without exposure to lipid transfection reagent complexed to a control ODN.  The 
control sequence used in these studies was ISIS 8424, a 20-mer phosphorothioate ODN 
composed of a scrambled sequence of the same base composition as ISIS 2302.  This sequence 
has been previously shown to have no biological target (Mehta, Stecker, et al., 2000).   Results 
demonstrate that transfection conditions did not exhibit any effect on ICAM-1 protein expression 
at the concentrations used (Figure 2.8).  There was no significant difference between basal  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  2.8. Effects of Oligofectamine on HeLa cell expression of ICAM-1 
Linearized mean fluorescence intensity of ICAM-1 expression is non-
significantly affected by the presence of the lipid (t-test p<0.05; n=3) 
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ICAM-1 expression in untreated cells and cells exposed to Oligofectamine.  Similarly, there was 
no significant change in IFNγ induced expression with Oligofectamine treatment (t-test, p<0.05). 
Cellular Delivery of Native and Caged ODNs 
     Several cationic lipids have been successfully used for the delivery of ODNs to various cell 
types.  In order to determine which lipid worked the best with this system, two of the most 
commonly used lipids, Oligofectamine and GenePorter (Genelantis, San Diego, CA) were 
compared.  Lipids were complexed with a 20-mer randomized phosphorothioate sequence with a 
5’FAM label (TriLink, San Diego, CA) to analyze cell delivery. Oligofectamine was 
significantly more 
efficient than GenePorter 
for the delivery of 20-mer 
phosphorothioate ODNs  
to HeLa cells (t-test 
p<0.05; n=3) (Figure 
2.9).      
     The 20-mer FAM-
labeled ODN sequence 
was also used to 
determine whether or not 
the attached cage group 
had any effect of the 
ability of lipids to 
conjugate to ODNs.  
Cells were transfected with 1.5 µg of either caged or native FAM-labeled ODNs complexed to 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.9. Comparison of lipid delivery agents 
Oligofectamine or GenePorter lipids were conjugated with 1µg of 
a 20-mer random phosphorothioate sequence with a 5’FAM label.  
Lipid complexes were found to have statistically significant 
differences in the delivery of ODNs to HeLa cells (t-test p<0.05; 
n=3) Each “n” replicate represents 20,000 cell events. 
Oligofectamine demonstrated more significant transfection ability 
based on flow cytometry analysis. 
 41 
Oligofectamine. Flow cytometric analysis determined that there was no significant difference in 
the ability of Oligofectamine to transport either caged or native PS ODNs (t-test p<0.05; n=3) 
(Figure 2.10).  
Knockdown of ICAM-1 Expression in HeLa cells 
Experiments were conducted to determine differences in ICAM-1 expression between cells 
treated with native or caged antisense before and after photo-release.  In this analysis, PE-
conjugated monoclonal antibodies were used to label ICAM-1 proteins.  Fluorescence dot plots, 
FL3 vs. FL5, of native, caged, and cage-flashed antisense treatments were compared to IFNγ 
positive and negative controls as an indication of gene knockdown (Figure 2.11).  In HeLa cells 
transfected with 1.5 µg of AS ODN, ICAM-1 expression in 78 ± 0.03% of whole cell 
populations were not up-regulated in response to IFNγ stimulation.  Comparatively, only 9.5 ± 
1.33% of cells remained unaffected in IFNγ-stimulated in controls (mean ± SEM) (Figure 2.12).  
Cell samples transfected with caged antisense had reduced antisense activity evidenced by 
decreases in the number of cells experiencing ICAM-1 knockdown.  These samples had reduced  
 
Figure 2.10. Confirmation of lipid-mediated transfection of caged 
and native ODNs  Oligofectamine showed no statistical differences in 
ability to complex to either native or caged 20-mer randomized 
phosphorothioate ODNs with 5’FAM labels (t-test p<0.05; n=3) 
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Figure 2.11. Effects of cage and cage-flashed antisense ODNs on ICAM-1 expression in 
HeLa cells.  Each graph represents 20,000 cell events analyzed by flow cytometry.   
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ICAM-1 expression in 66±1.15%, 25±1%, and 25.3±8% (mean±SEM) of total cell populations 
with 1.08 mM, 4.32 mM, and 6.48 mM DMNPE, respectively (Figure 2.12).  Cage-flashed 
samples were transfected with caged antisense that were subsequently photo-released through 
exposure to 40 J/cm2 of 365 nm light. These treatments had increased antisense activity over 
caged samples, approximately equal to 12%, 31.6%, and 6.3%  increases in percentages of cells 
with ICAM-1 knockdown.  These results correlate with hybridization studies that indicated  
 
 
 
 
 
reactions with smaller quantities of cage had more system “leak” where caged ODNs retained 
larger percentages of antisense activity (Figures 2.12, 2.5).  Reactions with the largest amount of 
cage (6.48mM) showed no significant difference in the number of cells affected by antisense 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.12. Effects of antisense treatments on knockdown of ICAM-1 protein expression 
Mean percentage of cells in knockdown region ± SEM.  Asterisks () indicate significant 
differences in photo-restoration activity from caged samples at equivalent DMNPE 
concentrations. Statistical differences between IFNγ-stimulated controls and caged antisense 
treatments are indicated ().  Statistical differences between antisense activity and photo-
restored (cage-flashed) activity are also shown (???  Student’s t-test were used with p<0.05 
considered significant with n=3 replicates, each “n” replicate representing 20,000 cell events. 
 
 
 
 
? 
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activity from IFNγ-stimulated controls (t-test p<0.05) (Figure 2.12).  This also correlates with 
hybridization data, which showed that reactions with 6.48mM cage had no hybridization activity 
with the antisense target (Figures 2.12, 2.4).  
     In addition to comparing the number of cells affected, mean linear fluorescence intensity 
(mFI) for all cell events was also used as an indication of protein expression in flow cytometry 
analysis.  Fluorescence intensities of antisense treatments indicated a knockdown of protein 
expression from 277.5 ± 10.1 in IFNγ-stimulated controls to 44.54 ± 1.26 (mean ± SEM) (Table 
2.2).  Cells transfected with caged antisense, 1.08 mM, 4.32 mM, or 6.48 mM, displayed 
antisense activities that were 40 ± 3%, 97 ± 5%, and 88 ± 7% of IFNγ-stimulated controls, 
respectively.  Of these, only the 1.08 mM caged antisense treatment was significantly different 
from the stimulated control (t-test p<0.05).  The mFI’s of all caged-flashed treatments showed 
significant differences from the mFI of antisense samples (t-test p<0.05).  Protein expression in 
cage-flashed samples decreased from caged samples by 24 ± 7%, 40  ± 15%, and 13 ± 2% for       
Table 2.2 . Relative effects of cage and caged-flashed ODNs on mean linear fluorescence 
intensities.  Fluorescent intensity relates to the stimulated expression of ICAM-1 protein as 
measured by flow cytometry.  
(mean ± SEM).  
Treatment Mean Fluorescence Intensity 
Statistical 
Significance 
IFNγ-Stimulated Control 277.5 ± 10.1  
Antisense (AS) 44.54 ± 1.26  
1.08mM Caged AS 112.4 ± 4.1  
1.08mM Cage Flashed AS 83.8 ± 6  ? 
4.32mM Caged AS 272.2 ± 22.6  
4.32mM Cage Flashed AS 157 ± 24.1  ? 
6.48mM Caged AS 244.8 ± 25.2  
6.48mM Caged Flashed AS 213.5 ± 18.7  ? 
Asterisks () indicate significant differences in photo-restoration activity from caged 
samples at equivalent DMNPE concentrations. Statistical differences between IFNγ-
stimulated controls and caged antisense treatments are indicated ().  Statistical differences 
between antisense activity and photo-restored (cage-flashed) activity are also shown (???  
Student’s t-test was used with p<0.05 considered significant with n=3 replicates, each “n” 
replicate representing 20,000 cell events. 
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1.08 mM, 4.32 mM, and 6.48 mM treatments, respectively.  None of these decreases were 
statistically significant (t-test p<0.05). 
     In summary, cell study results confirm hybridization study conclusions that there is a balance 
between maximum cage inactivation and maximum amount of photorestoration of antisense 
activity.  In both the low (1.08 mM) and high (6.48 mM) cage reactions, we see the extremes of 
caging efficiency where knockdown (1.08 mM) or photorestoration (6.48 mM) are minimal.  
However, at the midpoint, we see a 53% reduction in the percentage of cell population affected 
by antisense activity and a photo-recovery of antisense activity to within 21.6% of the native 
antisense control (Figure 2.12).   
Discussion 
     Our results indicate that photoremovable protecting groups can be covalently linked to a 
phosphorothioated AS ODN and introduced into cell culture as a means of controlling antisense 
effects on gene expression.  We have demonstrated the ability of a specific cage group, DMNPE, 
to reduce hybridization ability of phosphorothioate DNA. This ability to influence hybridization 
activity as measured by molecular beacon assays was previously demonstrated with 
phosphodiester DNA using the same cage group (Ghosn, Haselton, et al., 2005).  This work 
found that the ability of phosphorothioate antisense DNA to achieve gene knockdown varied 
based on the number of associated cage groups.  This trend was evidenced through hybridization 
assays as well as flow cytometry analyses of in vitro studies.  This points out one of the 
limitations to the employment of any cage compound in genetic therapy.  The problem of system 
“leak” occurs when too few cage moieties are attached to the effector molecule thus allowing 
activity to occur in the un-induced state.  However, excessive caging may make achieving 
complete photorestoration difficult.  Increasing the dosage of light applied to the system could 
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potentially lead to greater photorestoration of antisense activity in a larger percentage of the cell 
population.  Another potential way to circumvent this issue would be to photorelease the ODNs 
prior to transfection.  This “pre-flashing” method was previously demonstrated in studies 
involving the cage control of plasmid activity in HeLa cells (Monroe, McQuain, et al., 1999).  
However, although results from that study indicated an increase in photo-restored transgene 
expression, 100% photo-restoration was still not achieved (Monroe, McQuain, et al., 1999). 
     The solution to this problem lies in finding a balance between the minimum number of cage 
groups necessary to inactivate ODNs and the maximum number of cage groups that can be added 
before photoreactivation is too difficult to achieve.  Based on molecular beacon assays we found 
that the attachment of a specific number of cage groups results in a predictable blockade of 
hybridization inactivation as modeled by equation 5.   The attachment of 2-16 cage moieties per 
20-mer ODN resulted in some degree hybridization inactivation.  However, only about 8 cage 
groups (4.32 mM cage) per ODN were necessary to achieve 96% inhibition of hybridization 
activity.  
     Although hybridization inhibition required the attachment of a minimum number of cage 
groups, the maximum number of attached cage groups that would allow for significant 
photorestoration within cell light-dose tolerance limits needed to be determined.  Studies were 
done to determine the upper limit of light doses tolerated by HeLa cells so that these limitations 
could be used to optimize caging conditions within these constraints. In the evaluation of the 
effects of 365 nm  light on inducible ICAM-1 expression in HeLa cell culture, we compared light 
doses to minimize cytotoxicity due to photoexposure and maximize the amount photoactivating 
light available to cage inactivated ODNs.  Based upon light-dose results, we determined the 
maximum dose tolerated by cells before adverse effects on cell viability and immune response 
were observed to be 40 J/cm2.  Molecular beacon assays found that at least partial 
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photoresoration of bioactivity was achieved with each caged ODN (1.08 mM, 4.32 mM, and 6.48 
mM) studied.  The largest shift in cage and cage-flashed activity was seen with the attachment of 
8 cage groups (4.32mM cage) which demonstrated a 35% increase in hybridization activity upon 
exposure to 40 J/cm2 of 365 nm light.   
     Molecular beacon hybridization results were confirmed with flow cytometric cell based 
assays.  The 96% inhibition of antisense activity achieved with 4.32 mM of cage corresponded to 
inhibition of antisense activity in vitro such that only 25 ± 1% (mean ± SEM) of cell populations 
showed any antisense response with this same ODN.  This corresponded to a 97 ± 5% retention 
of interferon-stimulated ICAM-1 activity in vitro based on mFI protein expression analysis.  
Associated photoresoration of hybridization activity in vitro upon exposure to 365 nm light 
resulted in 40 ± 15% decrease of ICAM-1 expression in 56.7 ± 5.9% of the cell population. 
      These results show that antisense agents have the ability to significantly reduce target gene 
expression, but that they do not afford 100% control over biological systems.  In addition, these 
results show that cage compounds can be used to reversibly control the effects antisense agents 
have on gene expression.  Though similarly, caging chemistry control over antisense biological 
effects is also not 100%.  This study does, however, show that the degree of control can be 
maximized through the optimization of caging reaction conditions. 
     The use of chemical cages in the control of hybridization ability as a targeted delivery 
strategy was tested though the delivery of DMNPE-inactivated antisense agents to HeLa cells 
that were subsequently activated with near-UV light.  This research design was modeled after a 
system first introduced by Bennett et al and modified by Monroe et al, involving the monitoring 
of protein production in HeLa cell cultures via a cytokine inducible anti-ICAM-1 directed 
antisense system (Bennett, Condon, et al., 1994; Monroe, 2005).  It is possible that the efficiency 
of cage release ability within HeLa cells may be improved through the implementation of a 
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different cage moiety.  In addition to nitrobenzyl derivatives, there are a number of other cage 
group chemistries that have been used in the inactivation of a variety of biomolecules including 
carboxylic acids, calcium, and ATP (Shembekar, 2005; Bernardinelli, Haeberli, et al., 2005; 
Aarhus, Gee, et al., 1995) as well as in controlling the bioactivity of nucleobases, DNA, RNA, 
and modified ODN versions (Iwase, Kitani, et al., 2003; Shah, Rangarajan, et al., 2005; Heckel, 
Mayer, 2005; Ando, 2001).  Many of these newer cage groups have been thought to offer 
improved photochemical characteristics over the slow photolysis rates and low quantium yields 
observed with DMNPE-ATP (Wooton, 1989).  However, more recent experiments involving 
caged NAD, NADP and the antibiotic doxycycline have indicated that DMNPE release rates and 
product formation may have better photochemical characteristics than what was once thought, 
indicating that these characteristics may simply be dependent upon the moiety being caged 
(Cohen, Stoddard, et al., 1997; Cambridge, Geissler, et al., 2006).    
     Given the recent success with DNA (Ghosn, Haselton, et al., 2005; Tang, Dmochowski, 2005) 
cage compounds may provide the answer to overcoming targeting issues with antisense 
therapies.  The first and only antisense drug to have been granted FDA approval is Vitravene 
(formivirsen sodium), a phosphorothioate agent that is delivered via direct ocular injection and 
thus has restricted access to systemic circulation (de Smet, Meenken, et al., 1999; Crooke, 1998).  
Intended target sites of other antisense agents may not be as easily accessible as the retina and 
may necessarily rely on systemic delivery to reach target tissue.  For instance, one of the more 
recent antisense therapeutics being developed, Alicaforsen (ISIS 2302) is the first to target a 
gastrointestinal (GI) disease (Caprilli, Viscido, et al., 2002).  With the DMNPE caging group, we 
were able to deliver cage-inactivated ISIS 2302 to HeLa cells and administer targeted doses of 
light that resulted in the in vitro activation with no quantifiable negative effects on cell 
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population. This work demonstrates how cage chemistries might help to restrict activity of 
antisense agents, such as ISIS 2302, to optically available target tissues in disease treatment. 
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CHAPTER III 
 
CONCLUSIONS AND FUTURE CONSIDERATIONS 
 
Conclusions 
     The use of antisense strategies is a very promising field of gene therapy.  To date, there are 
several antisense drugs that have undergone or are in stage 3 clinical trials for FDA approval.  
One of the main areas of interest in the development of these therapeutics is how to control and 
target both their in vitro and in vivo effects to only cells and tissues of interest.  Photocleavable 
cage molecules have been used towards this goal of achieving the spatial and temporal control of 
phosphodiester nucleic acids (Ghosn, Haselton, et al., 2005).  This work demonstrated the ability 
to spatially- and temporally- control the effects of phosphorothioate antisense activity with 
photocleavable cage compounds in vitro.   In this way, nucleic acids therapeutics could be 
delivered to cells in inactive form and be induced for biological activity with light exposure.  
Few studies have been done to date attempting the photo-control of gene expression in cell or 
animal systems, and of those studies, none were able to demonstrate a relationship between 
degree of inactivation and degree of photorestoration (Monroe, McQuain, et al., 1999; Ando, 
2001; Shah, Rangarajan, et al., 2005).  We have shown that the covalent attachment of caging 
groups to a phosphorothioate ODN inhibits hybridization ability and that release of the cage 
groups through photo-triggering with near-UV light results in hybridization reactivation.  We 
have also shown that there are a minimal number of cage groups required to achieve inactivation 
and that this is balanced by a limit to the maximum number of cage groups that can be attached 
and released to result in photorestoration of bioactivity. In addition, we were able to introduce 
these biologically inactive, caged ODNs into cells and, upon exposure near-UV light, we were 
able to generate inhibition of target protein expression levels. 
 51 
     Antisense ODN inactivation was achieved through what has been referred to as a ‘statistical’ 
method of caging, in which a cage groups are nonspecifically attached to the DNA structure.  
Attachment of the cage compound 1-(4,5-dimethoxy-2-nitrophenyl)diazoethane (DMNPE) was 
assessed through spectrophotometry and gel electrophoresis and inhibition of activity was 
confirmed via a molecular beacon hybridization assay analyzed by fluorescence 
spectrophotometry.  Caged ODNs are unable to hybridize to the molecular beacon target, 
resulting in a lack of fluorescence as compared to native ODNs which are capable of fully 
hybridizing to the molecular beacon target. Several variations on the amount of cage were 
reacted with native ODNs and tested in an effort to find the minimal number of attached cage 
groups that resulted in maximal inactivation of the native species while allowing for 
photorestoration to be achieved within cell light dose tolerance limits.  Our results indicated an 
average of 41 % caging efficiency, corresponding to the association of 8 cage moieties, 
decreased hybridization ability by 96% and exposure to 365 nm light restored 35% of 
hybridization activity. 
     In addition, in vitro studies of this system were analyzed through the assessment of target 
protein expression levels using flow cytometry.  Results revealed that caged ODNs only affected 
protein expression levels in 25% of cell populations. Subsequent irradiation with 40 J/cm2 of 365 
nm light resulted in restoration of bioactivity as evidenced by the increase in percentage of cells 
affected to 56.7%.  This indicates that it is possible to achieve targeted delivery of antisense 
agent to cell systems with some control of bioactivity.  Our results also show that targeted 
photoactivation of caged ODNs can be achieved with light doses that impart little to no cell 
toxicity. 
     In conclusion, we have shown that cage compounds can be used to achieve spatio-temporal 
control of hybridization ability and protein synthesis in vitro through photocleavage mechanisms.  
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This work demonstrates a potential solution to achieving the systemic delivery of antisense drugs 
through the development of laboratory strategies to better study their reaction mechanisms and 
kinetics.  Current approaches that rely on more direct means of antisense delivery, such as direct 
tissue injections or oral delivery techniques, have variable, and usually very low, delivery 
success (Jaaskelainen, 2002).   
Future Directions 
     Despite the success achieved in this study with the use of the DMNPE caging compound, 
there are numerous alternative cage groups that have been developed in recent years, which may 
be more appealing in certain applications.  The most significant issue with DMNPE is its 
relatively low quantum yield, a characteristic that is intensified through the addition of the sulfur 
modifications on the DNA backbone (Walker, Reid, et al., 1988).  The development of cage 
groups with higher quantum yields will allow for more rapid photolysis at longer wavelengths, 
which will be easier for living tissue to tolerate.  Recently, a 7-N,N-diethylamino-4-
hydroxymethyl coumarin cage group conjugated to a carboxylic acid was shown to have a 
quantum yield of 0.11 when photolysed with a 10 ns pulse at wavelengths greater than 400 nm 
(Shembekar, 2005).  This exceeds the quantum yields of 0.09 that have been been calculated for 
DMNPE-caged ODNs (Ghosn, Haselton, et al., 2005).  In addition, quantum yields of visible 
light responsive groups have the potential to be significantly enhanced through two-photon 
excitation (Denk, Strickler, et al, 1990).  Ultimately, the achievement of caged ODNs with a 
visible, longer and deeper penetrating, wavelength responsive group will eliminate most of the 
concern with cytotoxic light effects, especially when coupled with TPE systems which will allow 
for these lower energy photons to combine their effects to accomplish rapid photolysis.   
     Overall, caging efficiencies achieved with any cage group, regardless of the photoresponsive 
wavelength, will be greatly enhanced by the ability to achieve site-specific placement of a 
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specific number of cage moieties to a DNA molecule.  The methods employed in these studies 
were ‘statisical’ or relatively randomized caging conditions in which variations of reaction 
conditions resulting in a range of caging efficiencies were compared for optimization.  The 
ability to cage targets on the backbone to achieve very specific and reproducible caging 
efficiencies will allow for overall optimization on a much larger scale.  However, there is a great 
deal of difficulty in reaching that goal unless there is a clear understanding of the mechanism 
involved, specifically on where the cage attaches.  It was originally theorized that caging took 
place along the negative backbone of the DNA molecule, a theory supported by the increased 
affinity of the cage group for the more negatively charged phosphorothioate backbone (Monroe, 
McQuain, et al., 1999; Ghosn, Haselton, et al., 2005).  However, this may not necessarily be the 
case.  To be certain, the most reliable means of single site-specific cage incorporation is to 
incorporate a photolabile cage during solid-phase synthesis.  Unfortunately, this gives rise to a 
number of other potential complications, as exemplified in a study be Iwase et al where a single 
nitroveratryloxycarbonyl (NVOC) cage that was incorporated onto a thymine required 5 hours, 
the equivalent to 61.2 J/cm2, of 355 nm light to uncage (Iwase, Kitani, et al., 2003).  Similarly, in 
a recent work by Krock et al, variations of 2-nitrobenzyl and 2-nitrophenyl ethyl groups were 
shown to be capable of complete blockage of the activity of phosphoramidites (Krock, 2005).  
The cage groups used were responsive to slightly longer (366 nm) wavelengths but showed very 
slow release kinetics.   
     Comparisons between light, medium, and heavily caged solutions demonstrated that residual 
active ODN present in less heavily caged samples results in system “leak” where uncaged ODNs 
still exhibit hybridization ability.  In order to address the problem of system leak, affinity 
chromatography methods could be employed to separate native from caged ODNs.  It has been 
shown that nucleic acids can be fractionated on hydroxyapatite (HA) columns based on 
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interactions between the negative charges on the DNA backbone and the positive charges in the 
calcium ions composing the crystalline structure of the HA (Bernardi, 1965).  Both single-
stranded and double-stranded DNA can be adsorbed onto HA columns with a low (0.005-0.01 
M) sodium phosphate buffer but desorption will be fractionated based on differences in their 
affinities for increasing molarities of phosphate buffer over their affinities for the column 
(Bernardi, 1965; Ahnstrom, Erixon, 1981).  The affinities of several types of DNA for HA were 
studied and it was found that DNA which demonstrates lower electrophoretic mobility has 
corresponding lower binding affinity to HA (Bernardi, 1965).  Therefore, as caged ODNs have 
also demonstrated decreased electrophoretic mobility than native ODNs, presumably due to 
phosphate alkylation, HA columns could be used as a means of purifying caged product by 
fractionating it out from the mixed reaction product.  
     In addition to cage group considerations, it is also essential to perform a thorough analysis of 
delivery systems to find the optimum transport mechanism for a specific application.  Though in 
this study, comparisons between two different lipid formulations, GenePorter (Genelantis, 
Sandiego, CA) and Oligofectamine (Invitrogen, Carlsbad, CA), were done to determine the best 
carrier for the native ODNs.  For more in-depth analysis, the OliGreen Assay has been used to 
evaluate the interactions between lipid carriers and different DNA structures (Sundaram, 
Viriyayuthakorn, et al., 2005).  The OliGreen dye fluoresces when bound to single-stranded, 
non-lipid associated DNA ODNs and is unable to conjugate to lipid alone or lipid-ODN 
lipoplexes (Gray, Basu, et al., 1997).  Therefore, in order to identify the lipid that best associates 
with caged ODN, the OliGreen assay could be employed to achieve more optimal cell delivery of 
the asODNs used in this study.   
    Despite peaked interest in newer antisense agents such as morpholinos and PNAs, there 
remain a number of advantages to phosphorothioate ODNs.  Over the past decade, numerous 
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studies have compared several ODNs types in an effort to determine the superior for antisense 
treatments (Baker, Lot, et al., 1997; Yoo, Bochkareva, et al., 2004; Grunweller, Wyszko, et al., 
2003).  Of these studies, those that actually performed analysis in cell systems typically used 
only one or two delivery methods to compare all of the ODNs.  From our own studies, we have 
seen vast differences between transfection ability of a number of different cationic lipid reagents 
in a single cell type.  Similarly, we expect that different ODN chemistries will have differing 
optimal delivery mechanisms.  Studies such as the research conducted by Sazani et al, have 
pointed out the ineffectiveness of naked and scrape-loading delivery methods for the transfection 
of phosphorothioates (Sazani, 2001).  Though the feasibility of delivery via conjugation to a 
cationic lipid was also explored, the results may have been more positive had a thorough 
comparison and evaluation of several cationic lipid variations been conducted (Sazani, Kang, et 
al., 2001).  Although some comparisons have been made among various lipid formulations to 
determine which carrier type improves cellular delivery of AS ODNs, again results of such 
studies are likely to vary based on ODN formulation, cell type, and the emergence of newer 
lipids and have not taken into consideration nonspecific accumulations of AS ODNs within 
cellular compartments (Ruponen, Yla-Herttuala, et al., 1999).    
     Finally, in addition to monitoring cell target protein levels, a complete analysis of antisense 
effects in this system requires direct evaluation of the ability of the asODN to inhibit mRNA 
synthesis.  Reverse transcription polymerase chain reaction (RT-PCR) studies will allow for the 
quantification of target mRNA levels and allow us to draw correlations between the control of 
translation and protein expression.  In addition, both protein and mRNA level results obtained 
through the flow cytometry methods used herein and RT-PCR methods could be verified through 
western and northern blotting methods, respectively, as a less quantitative confirmation of 
results.  However, the results herein demonstrate a promising step towards one of the idealized 
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goals of cell and tissue engineering, which is to be able to achieve targeted delivery and 
activation of antisense therapeutics only in cells and tissue of interest. 
      
 57 
REFERENCES 
 
Aarhus, R., Gee, K., and Lee, H. (1995) “Caged cyclic ADP-ribose” Journal of Biological 
Chemistry.  270(13): 7745-7749. 
 
Ahnstrom, G., and Erixon, K. (1981) “Measurement of strand breaks by alkaline denaturation 
 and hydroxyapatite chromatography” DNA Repair: A Laboratory Manual of Research 
Procedures, E.C., Friedberg and P.C. Hanwalt, (Eds.) Dekker, New York. 
 
Akhtar, S., and Juliano, R. (1992) “Cellular uptake and intracellular fate of antisense 
oligonucleotides” Trends in Cell Biology. 2(5):139-144. 
 
Akhtar, S., Hughes, M., et al. (2000) “The delivery of antisense therapeutics” Advanced Drug 
Delivery Reviews.  44: 3-21. 
 
Amarzguioui, M., Holen, T., et al (2003) “Tolerance for mutations and chemical modifications in 
a siRNA” Nucleic Acids Research. 31:589-595. 
 
Arroyo, J., Jones, P., Porter, N., and Hatchell, D. (1997) “In-vivo photoactivation of caged 
thrombin” Thrombosis and Haemostasis. 78(2):791-793. 
 
Baker, B., Lot, S., et al. (1997) “2’-O-(2-methoxy)ethyl-modified anti-intercellular adhesion  
molecule 1 (ICAM-1) oligonucleotides selectively increase the ICAM-1 mRNA level and 
inhibit formation of the ICAM-1 translation initiation complex in human umbillical vein 
endothelial cells” Journal of Biological Chemistry. 272(18):11994-12000. 
 
Banerjee, A. Grewer, C.,et al (2003) “Toward the development of new photolabile protecting  
groups that can rapidly release bioactive compounds upon photolysis with visible Light”  
Journal of Organic Chemistry. 68(22):8361-8367. 
 
Bartsch, M., Weeke-Klimp, A., et al. (2005) “Optimized targeting of polyethylene glycol 
stabalized anti-intercellular adhesion molecule 1 oligonucleotide/lipid particles to liver  
sinusoidal endothelial cells”  Molecular Pharmocology.  67(3):883-890. 
 
Bennett, C., Condon, T., et al. (1994) “Inhibition of endothelial cell adhesion molecule 
expression with antisense oligonucleotides” Journal of Immunology.  152(7): 3530-3540. 
 
Bennett, C. and Cowsert, L. (1999) “Application of antisense oligonucleotides for gene 
 Functionalization and target validation” Current Opinion in Molecular Therapy. 
 1(3):359-371. 
 
Bernardi, G. (1965) “Chromatography of nucleic acids on hydroxyapatite” Nature. 
 206(986):779-783. 
 
 
 
 58 
Bernardinelli, Y., Haeberli, C., and Chatton, J. (2005) “Flash photolysis using a light emitting
 diode: an efficient, compact, and affordable solution” Cell Calcium.  37:565-572. 
 
Bertrand, J., Pottier, M., et al (2002) “Comparison of antisense oligonucleotides and siRNAs in
 cell culture and in vivo” Biochemistry and Biophysical Research Communications.
 296(4): 1000-1004.  
 
Boehm, U, Klamp, T., et al (1997) “Cellular responses to interferon-gamma” Annual Reviews in
 Immunology. 15:749-795. 
 
Brown, D., Kang, S., et al (1994) “Effect of phosphorothioate modification of 
oligodeoxynucleotides on specific protein-binding” Journal of Biological Chemistry.
 269(43):26801=26805. 
 
Cambridge, S., Geissler, D., Keller, S., and Curten, B. (2006) “A Caged doxycycline analogue
 for photoactivated gene expression” Angewandte Chemie International Edition.  
45: 2229-2231. 
 
Caprilli, R., Viscido, A., and  Guagnozzi, D. (2002) “Review article: biological agents in the
 treatment of Crohn’s disease” Ailmentary and Pharmicology and Therapeutics
 16(9):1579-1590. 
 
Chaulk, S., and MacMillan, A. (1998) “Caged RNA: photo-control of a ribozyme reaction”
 Nucleic Acids Research. 26(13):3173-3178. 
 
Chiang, M., Chan, M. et al. (1991) “Antisense oligonucleotides inhibit intercellular adhesion
 molecule-1 expression by two distinct mechanisms” Journal of Biochemistry.  266(27):
 18162-18171. 
 
Cohen, B., Stoddard, B., and Koshland, D. (1997) “Caged NADP and NAD.  Synthesis and
 characterization of functionally distinct caged compounds” Biochemistry 
 36(29): 9035-9044. 
 
Cook, P. (1993) “Medicinal chemistry strategies for antisense research” Antisense Research and
 Applications,  Crooke & LeBleu (eds) CRC Press, Boca Raton, FL..   
 
Corrie, J., and Trentham, D. (1993) “Caged nucleotides and neurotransmitters”  Bioorganic
 Photochemistry, Morrison, H (ed). Wiley, New York.   
 
Crooke, S. and Bennett, C. (1996) “Progress in antisense oligonucleotide therapeutics” Annual
 Review of Pharmacology and Toxicology.  36:107-129. 
 
Crooke, S. (1998) “Molecular mechanisms of antisense drugs: RNaseH” Antisense & 
 Nucleic Acid Drug Development.  8(2): 133-140. 
 
 
 59 
Crooke, S. (2004) Progress in antisense technology. Drug Delivery Systems in Cancer Therapy.
 Brown, D (ed.)  Totowa, Humana Press: 311-346. 
 
Denk, W., Strickler, J., et al (1990) “Two-photon laser scanning fluorescence microscopy”
 Science. 248(4951):73-76. 
 
de Smet, M. Meenken, C. and van den Horn, G.  (1999) “Formiversen – a phosphorothioate
 oligonucleotide for the treatment of CMV”  Taylor and Francis, 7:3-4. 
 
Diaspro, A., and Robello, M. (2000) “Two-photon excitation of fluorescence for three- 
 dimensional optical imaging of biological structures” Journal of Photochemistry 
 and Photobiology B:Biology. 55(1):1-8. 
 
Dustin, M., Rothlein, R., et al. (1986) “Induction by IL-1 and interferon-gamma:  tissue
 distribution, biochemistry, and function of a natural adherence molecule (ICAM-1)”
 Journal of Immunology.  137(1): 245-254.   
 
Fedoryak, O., and Dore, T. (2002) “Brominated hydroxyquinoline as a photolabile  
 protecting group with sensitivity to multiphoton excitation” Organic Letters.  
4(20):3419-3422. 
 
Fire, A., Xu, S., Montgomery, M., Kostas, S., Driver, S., and  Mello, C. (1998) “Potent and
 specific genetic interference by double-stranded RNA in Caenorhabditis Elegans” 
 Nature. 391:806-811. 
 
Furuta, T., Wang, S., et al (1999) “Brominated 7-hydroxycoumarin-4-ylmethyls: photolabile
 protecting groups with biologically useful cross-sections for two photon photolysis”
 Proceedings of the National Academy of the Sciences. 96(4):1193-2000. 
 
Gewirtz, A. (1999) “The prospects for antisense therapy” Hospital Practice.  34(10): 97-107.   
 
Ghosn, B., Haselton, F., Gee, K., and Monroe, W. (2005) “Control of DNA hybridization with
 photocleavable adducts” Photochemistry and Photobiology.  81(4):953-959. 
 
Gorbunoff, M. (1984) “The interaction of poteins with hydroxyapatite” Analytical Biochemistry.
 136: 433-439. 
 
Gray, G., Basu, S., and Wickstrom, E. (1997) “Transformed and immortalized cellular uptake of
 oligodeoxynucleotide phosphorothioates, 3’-alkylamino oligodeoxynucleotides, 2’-O
 methyl oligoribonucleotides, oligodeoxynucleoside methylphosphonates, and peptide
 nucleic acids” Biochemical Pharmacology. 53:1465-1476. 
 
Grunweller, A., Wyszko, E., et al (2003) “Comparison of different antisense strategies in
 mammalian cells using locked nucleic acids, 2’-O-methyl RNA, phosphorothioates and
 small interfering RNA” Nucleic Acids Research. 31(12):3185-3193. 
 
 60 
Hammond, S.,  Berstein, E., Beach, D., and Hannon, G. (2000) “An RNA-directed nuclease
 mediates post-transcriptional gene silencing in Drosophilia cells”  Naure.  
404(6775):293-296. 
 
Heckel, A. and Mayer, G. (2005) “Light regulation of aptamer activity: an anti-thrombin aptamer
 with caged thymidine nucleobases” Journal of the American Chemical Society.   
127(3): 822-823. 
 
Hughes, M., Hussain, M., Nawaz, Q., Sayyad, P., and Akhtar, S. (2001) “The cellular delivery of
 antisense oligonucleotides and ribozymes” Drug Discovery Today. 6(6):303-315. 
 
Hughes, J., Astriab, A., et al (2000) “In vivo transport and delivery of antisense  
oligonucleotides” Methods in Enzymology. 313:342-358. 
 
Iwase, R., Kitani, A., et al (2003) “Synthesis of antisense oligonucleotides containing 
photocleavable protecting groups on the thymine bases and their photoinduced duplex
 formation” Nucleic Acids Research Supplement. (3):61-62. 
 
Kaplan, J., Forbush, B., and Hoffman, J. (1978) “Rapid photolytic release of adenosine 5’ 
triphosphate form a protected analogue: utilization by the Na:K pump of human red
 blood cell ghosts” Biochemistry.  17(10):1929-1935. 
 
Kurreck, J., Wyszko, E., Gillen, C., and Erdmann, V. (2002) “Design of antisense
 oligonucleotides stabilized by locked nucleic acids” Nucleic Acids Research. 
 30:1911-1918. 
 
Kurreck, J. (2003) “Antisense technologies.  improvement through novel chemical 
modifications” European Journal of Biochemistry.  270(8): 1628-1644. 
 
Lebedeva, I. and Stein, C. (2001) “Antisense oligonucleotides: promise and reality”Annual 
Review of Pharmacology and Toxicology.  41:403-419. 
 
Liu, X., Nakamura, K., et al. (2006) “Initial mechanistic studies of antisense targeting in Cells” 
The Journal of Nuclear Medicine.  47(2): 360-368. 
 
Lucas, B., Van Rompaey, E., et al. (2004) “On the biological activity of anti-ICAM-1  
 oligonucleotides complexed to non-viral carriers” Journal of Controlled Release. 
 96(1):207-219. 
 
Maksimenko, A., Gottikh, M., et al (1999) “Physico-chemical and biological properties of 
antisense phosphodiester oligonucleotides with various secondary structures” 
Nucelosides and Nucleotides. 18((9):2071-2091. 
 
Masarjian, L,, dePeyster, A., Levin, A., and Monteith, D. (2004) “Distribution and excretion of a 
phosphorothioate oligonucleotide in rats with experimentally induced renal injury” 
Oligonucleotides.  14(4): 299-310. 
 61 
Mayer, G., and Heckel, A. (2006) “Biologically active molecules with a ‘light switch’”  
 Angewandte Chemis International Edition. 45(30):4900-4921.  
 
Mehta, R., Stecker, K., et al (2000) “Intercellular adhesion molecule-1 suppression in skin by 
topical delivery of anti-sense oligonucleotides” Journal of Investigative Dermatology. 
115(5):805-812. 
 
McCray, J., and Trentham, D. (1989) “Properties and uses of photoreactive caged compounds”
 Annual Reviews of Biophysics and Biophysical Chemistry. 18:239-270. 
 
Momotake, A., Lindegger, N., Niggli, E., Barsotti, R., and Ellis-Davis, G. (2006) “The 
 nitrodibenzofuran chromophore: a new caging group for ultra-efficient photolysis in 
living cells” Nature Methods. 3(1): 35-40. 
 
Monroe, W., and Haselton, F. (2005) “Light reversible suppression of DNA bioactivity with cage
 compounds” Dynamic Studies in Biology: Phototriggers, Photoswitches, and Caged
 Biomolecules. Goeldner and Givens (eds) Wiley-VCH,Weinheim. 
 
Monroe, W., McQuain, M., et al. (1999) “Targeting expression with light using caged DNA”
 Journal of Biological Chemistry.  274(30): 20895-20900. 
 
Morcos, P. (2001) “Achieving efficient delivery of morpholino oligos in cultured cells” Genesis.
 30(3):94-102. 
 
Mukherjee, S. and Bhattacharyya, D. (2004). “Effect of phosphorothioate chirality on the  
Grooves of DNA double helices: a molecular dynamics study” Biopolymers.  
73(2): 269-282. 
 
Mulligan, R. (1993) “The basic science of gene therapy” Science. 260(5110):926-932. 
 
Nakamura, Y., Oda, S., et al (1991) “How does RNase H recognize a DNA-RNA Hybrid?”
 Proceedings of the National Academy of Sciences. 88:11535-11539. 
 
Nakai, D., Seita, T, et al (1996) “Cellular uptake mechanisms for oligonucleotides: involvement
 of endocytosis in the uptake of phosphodiester oligonucleotides by a human colorectal
 adenocarcinoma cell line, HCT-15”  Journal of Pharmacology and Experimental
 Therapeutics. 278(3):1362-1372. 
 
Nedbal, W., Tomakidi, P., et al. (2002) “Antisense-mediated inhibition of ICAM-1 expression: a 
 Therapeutic strategy against inflammation of human periodontal disuse” Antisense 
 Nucleic Acid Drug Development. 12(2):71-78. 
 
Nesterova, M. and Cho-Chung, Y. (2004) “Killing the messenger: antisense DNA and siRNA”
 Current Drug Targets. 5(8):683-689. 
 
 62 
Nicklin, S., Buening, H., et al (2001) “Efficient and selective AAV2-mediataed gene transfer
 directed to human vascular endothelial cells” Molecular Therapeutics. 4(3):174-181. 
 
Obika, S., Hemamayi, R., et al (2001) “Inhibition of ICAM-1 gene expression by antisense 2’,4’
 BNA oligonucleotides” Nucleic Acids Research, Supplement.  1(1):145-146. 
 
Orum, H., Wolter, A., and Kongsbak, L. (2003) “Locked nucleic acids (LNA) and medical
 applications” Letters in Popular Science.  10: 325-334. 
 
Patil, S., Rhodes, D., and Burgess, D. (2005) “DNA-based therapeutics and DNA delivery
 systems:  A comprehensive review” The AAPS Journal.  7(1):E61-77. 
 
Pelliccioli, A., and Wirz, J. (2002) “Photoremovable protecting groups: reaction mechanisms and
 applications” Photochemisty and Photobiological Science.  1: 441-458. 
 
Raghavan, A., Ogilvie, R., et al. (2002) “Genome-wide analysis of mRNA decay in resting and  
Activated primary human T lymphocytes” Nucleic Acids Research. 30: 5529-5538. 
 
Roebuck, K. and Finnegan, A. (1999) “Regulation of intercellular adhesion molecule-1 (CD54)
 gene expression” Journal of Leukocyte Biology.  66: 878-888. 
 
Roth, C. and Sundaram, S. (2004) “Engineering synthetic vectors for improved DNA delivery:
 insights from intracellular pathways” Annual Reviews in Biomedical Engineering. 
 6:397-426. 
 
Roth, C. (2005) “Molecular and cellular barriers limiting the effectiveness of antisense 
 oligonucleotides” Biophysical Journal. 89(4):2286-2295. 
 
Ruponen, M., Yla-Herttuala, S., and Urtti, A. (1999) “Interactions of polymeric and liposomal
 gene delivery systems with extracellular glycosaminoglycans: physicochemical and
 transfection studies” Biochimica et Biophysica Acta.  1415(2):331-341. 
 
Sazani, P., Kang, S., et al. (2001) “Nuclear antisense effects of neutral, anionic, and  
 cationic oligonucleotide analogs” Nucleic Acids Research. 29(19):3965-3974. 
 
Schworer, M. and Wirz, J. (2001) “Photochemical reaction mechanisms of  2-Nitrobenzyl
 compounds in solution” Helvetica Chimica Acta 84(6):1441-1458. 
 
Shah, S., Rangarajan, S., and Friedman, S. (2005) “Light-activated RNA interference” 
 Angewandte Chemie International Edition. 44(9):1328-1332. 
 
Shembekar, V., Chen, Y., Carpenter, B., and Hess, G. (2005) “A protecting group for 
 Carboxylic acids that can be photolyzed by visible light” Biochemistry. 
 44(19):7107-7114. 
 
 63 
Summerton, J., Stein, D., et al (1997) “Morpholino and phosphorothioate antisense oligomers
 compared in cell-Free and in-cell systems” Antisense Nucleic Acid Drug Development.
 7:63-70. 
 
Summerton, J. (1999) “Morpholino antisense oligomers: the case for an RNaseH-independent
 structural type” Biochimica et Biophysica Acta. 1489:141-158. 
 
Sundaram, S., Viriyayuthakorn, S., and Roth, C. (2005) “Oligonucleotide structure influences the
 interactions between cationic polymers and oligonucleotides” 
  
Takei, Y., Kadomatsu, K., et al (2005) “Morpholino antisense oligomer rargeting human
 midkine: Its application for cancer therapy” International Journal of Cancer.  
114:490-497. 
 
Tang, X., and Dmochowski, I. (2005) “Phototriggering of caged fluorescent  
 oligodeoxynucleotides” Organic Letters. 7(2):279-282. 
 
Tomari, Y. and Zamore, P. (2006) “Perspective: machines for RNAi”  Genes and Development 
 19(5):517-529. 
 
van de Stolpe, A., and van der Saag, P. (1996) “Intercellular adhesion molecule-1” Jounral of
 Molecular Medicine. 74(1):13-33. 
 
Vickers, T. et al. (2003) “Efficient reduction of target RNAs by small interfering RNA and
 RNase H-dependent antisense agents” Journal of Biological Chemistry.   
278(9): 7108-7118. 
 
Walder, R., and Walder, J. (1988) “Role of RNase H in hybrid-arrested translation by antisense
 oligonucleotides” Proceedings of the National Academy of Sciences. 85:5011-5015. 
 
Walker, J., Reid, G., McCray, J., and Trentham, D. (1988) “Photolabile 1-(2-nitrophenyl) 
ethyl phosphate esters of adenine nucleotide analogues.  synthesis and mechanism of
 photolysis”  Journal of the American Chemical Society.  110: 7170-7177. 
 
Wells, D. (2004) “Gene therapy progress and prospects:  electroporation and other physical
 methods” Gene Therapy.  11:1363-1369. 
 
Wootton, J. and Trentham, D. (1989) “’Caged’ compounds to probe the dynamics of cellular
 processes: synthesis and properties of some novel photosensitive P-2-nitrobenzyl esters
 of nucleotides”  Photochemical Probes in Biochemistry. Nielsen, Ed.  Kluwer Academic
 Publishers: 277-296. 
 
Wu, H., Lima, W., Zhang, H., Fan, A., Sun, H., and Crooke, S. (2004) “Determination of the role
 of the human RNase H1 in the pharmacology of DNA-like antiense drugs” The Journal of
 Biological Chemistry. 279(17):17181-17189. 
 
 64 
Yacyshyn, B., Barish, C., Goff, J., et al. (2002) “Dose ranging pharmoacokinetic trial of high
 dose Alicaforsen (intercellular adhesion molecule-1 antisense oligodeoxynucleotide)
 (ISIS 2302) in active Crohn’s disease” Alimentary Pharmacology & Therapeutics. 
 16(10): 1761. 
 
Yachyshyn, B., Chey, W., Goff, J., et al. (2002) “Double blind, placebo controlled trial of the
 remission inducing and steroid sparing properties of an ICAM-1 antisense
 oligodeoxynucleotide, Alicaforsen (ISIS 2302), in active steroid dependent Crohn’s
 disease”  Gut. 51; 30-36. 
 
Yoo, B., Bochkareva, E., et al (2004) “2’-O-methyl-modified phosphorothioate antisense 
 oligonucleotides have reduced non-specific effects in vitro” Nucleic Acids Research.
 32(6):2008-2016. 
 
Zamecnik, P., and Stephenson, M. (1978) “Inhibition of Rous sarcoma virus replication and cell
 transformation by a specific oligodeoxynucleotide” Proceeding of the National Academy
 of Sciences. 75(1):280-284. 
 
Zhang, Y., Rusckowski, M., et al (2001) “Cationic liposomes enhance cellular/nuclear 
localization of 99mTc-antisense oligonucleotides in target tumor cells” Cancer Biotherapy
 & Radiopharmaceutical. 16(5):411-419. 
 
Zhao, Y., Zheng, Q., et al (2004) “New caged coumain fluorophores with extraordinary uncaging
 cross sections suitable for biological imaging applications” Journal of The American
 Chemical Society. 126(14):4653-4663. 
 
 65 
APPENDIX: RAW CELL DATA 
 
 
 
 
Figure 2.7(a):        
sample 
time 
(s) 
lin mean 
(of 98%) # of cells 
IFNg - 0 13.33 20000 
IFNg + 0 115.41 20000 
IFNg + 0 135.95 20000 
IFNg + 15 136.01 20000 
IFNg + 15 115.02 20000 
IFNg + 15 89.55 20000 
IFNg + 30 138.77 20000 
IFNg + 30 104.83 20000 
IFNg + 30 118.75 20000 
IFNg + 60 126.05 20000 
IFNg + 60 118.25 20000 
IFNg + 60 108.97 20000 
IFNg + 180 41.98 12380 
IFNg + 180 57.02 20000 
IFNg + 180 44.52 3460 
IFNg + 300 57.36 1980 
IFNg + 300 LOST    
IFNg + 300 45.61 14768 
sample 
time 
(s) 
lin mean 
(of 98%) # of cells 
1.5 ug AS 0 70.2 20000 
1.5 ug AS 0 66.12 20000 
1.5 ug AS 0 59.35 20000 
1.5 ug AS 15 65.27 20000 
1.5 ug AS 15 68.56 20000 
1.5 ug AS 15 66.67 20000 
1.5 ug AS 30 73.06 20000 
1.5 ug AS 30 68.54 20000 
1.5 ug AS 30 66.59 20000 
1.5 ug AS 60 67.95 20000 
1.5 ug AS 60 70.36 20000 
1.5 ug AS 60 58.65 20000 
1.5 ug AS 180 27 20000 
1.5 ug AS 180 18.4 6780 
1.5 ug AS 180 18.9 11319 
1.5 ug AS 300 48.62 3180 
1.5 ug AS 300 14.94 20000 
1.5 ug AS 300 31 20000 
 
Time Averages Normalized std. dev. std. error 
0 112.35 100.00 14.52 10.27 
15 100.20 89.20 23.27 16.45 
30 107.45 95.60 17.06 9.85 
60 104.43 92.90 8.55 4.94 
180 38.51 57.80 8.05 4.65 
IFNg+ 
300 42.16 63.20 8.31 4.80 
Time Averages Normalized std. dev. std. error 
0 51.89 46.20 5.48 3.16 
15 52.41 46.70 0.81 0.47 
30 56.07 49.90 3.32 1.92 
60 52.32 46.60 6.18 3.57 
180 12.10 18.20 4.83 2.79 
1.5 ug 
AS 
300 22.19 33.30 16.85 9.73 
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Figure 2.12: 
 Pos Control Neg Control AS 
1.08mM   
Caged AS 
1.08mM 
Cage 
Flashed AS 
4.32mM 
Caged AS 
4.32mM 
Cage 
Flashed AS 
6.48mM 
Caged AS 
n=1 291.93 21.27 46.22 109.28 92.47 290.25 138.64 241.39 
n=2 282.56 22.13 42.07 107.36 86.73 299.19 127.65 290.05 
n=3 258 20.92 45.33 120.43 72.32 227.26 204.74 203 
average 277.50 21.44 44.54 112.36 83.84 272.23 157.01 244.81 
std. dev. 17.52 0.62 2.18 7.06 10.38 39.20 41.70 43.63 
sqrt n=3 1.73 1.73 1.73 1.73 1.73 1.73 1.73 1.73 
std. error 10.12 0.36 1.26 4.07 5.99 22.63 24.07 25.19 
 
IFNg vs 1.08mM C  IFNg vs 4.32mM C  IFNg vs 6.48mM C  
t-Test: Paried Two Sample for Means t-Test: Paired Two Sample for Means t-Test: Paired Two Sample for Means 
         
  Variable 1 Variable 2   Variable 1 Variable 2   Variable 1 Variable 2 
Mean 277.4966667 112.3566667 Mean 277.4966667 272.2333333 Mean 277.4966667 244.8133333 
Variance 307.0392333 49.80563333 Variance 307.0392333 1536.931433 Variance 307.0392333 1903.215033 
Observations 3 3 Observations 3 3 Observations 3 3 
Pearson 
Correlation 
-
0.918267065  
Pearson 
Correlation 0.926824371  
Pearson 
Correlation 0.650714671  
Hypothesized 
Mean Difference 0  
Hypothesized 
Mean Difference 0  
Hypothesized 
Mean Difference 0  
df 2  df 2  df 2  
t Stat 11.83650476  t Stat 0.381638367  t Stat 1.623783674  
P(T<=t) one-tail 0.003531047   P(T<=t) one-tail 0.369730481  P(T<=t) one-tail 0.122953493  
t Critical one-tail 2.91998558  t Critical one-tail 2.91998558  t Critical one-tail 2.91998558  
P(T<=t) two-tail 0.007062093  P(T<=t) two-tail 0.739460961  P(T<=t) two-tail 0.245906987  
t Critical two-tail 4.30265273   t Critical two-tail 4.30265273   t Critical two-tail 4.30265273   
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1.08 CvsCF   4.32 CvsCF   6.48 CvsCF   
t-Test: Paired Two Sample for Means t-Test: Paired Two Sample for Means t-Test: Paired Two Sample for Means 
         
  Variable 1 
Variable 
2   Variable 1 Variable 2   Variable 1 Variable 2 
Mean 112.3566667 83.84 Mean 272.2333333 157.01 Mean 244.8133333 213.4533333 
Variance 49.80563333 107.7697 Variance 1536.931433 1738.8097 Variance 1903.215033 1045.726633 
Observations 3 3 Observations 3 3 Observations 3 3 
Pearson Correlation 
-
0.914485578  Pearson Correlation 
-
0.999839912  Pearson Correlation 0.963144985  
Hypothesized Mean 
Difference 0  
Hypothesized Mean 
Difference 0  
Hypothesized Mean 
Difference 0  
df 2  df 2  df 2  
t Stat 2.892586662  t Stat 2.466920312  t Stat 3.570639422  
P(T<=t) one-tail 0.050811501 * P(T<=t) one-tail 0.066223095  P(T<=t) one-tail 0.035133925 * 
t Critical one-tail 2.91998558  t Critical one-tail 2.91998558  t Critical one-tail 2.91998558  
P(T<=t) two-tail 0.101623002  P(T<=t) two-tail 0.132446191  P(T<=t) two-tail 0.070267851  
t Critical two-tail 4.30265273   t Critical two-tail 4.30265273   t Critical two-tail 4.30265273   
AS vs 1.08mM CF  AS vs 4.32mM CF  AS vs 6.48mM CF  
t-Test: Paired Two Sample for Means t-Test: Paired Two Sample for Means t-Test: Paired Two Sample for Means 
  Variable 1 
Variable 
2   Variable 1 Variable 2   Variable 1 Variable 2 
Mean 44.54 83.84 Mean 44.54 157.01 Mean 44.54 213.4533333 
Variance 4.7737 107.7697 Variance 4.7737 1738.8097 Variance 4.7737 1045.726633 
Observations 3 3 Observations 3 3 Observations 3 3 
Pearson Correlation 
-
0.038372318  Pearson Correlation 0.435553598  Pearson Correlation 
-
0.595399559  
Hypothesized Mean 
Difference 0  
Hypothesized Mean 
Difference 0  
Hypothesized Mean 
Difference 0  
df 2  df 2  df 2  
t Stat 
-
6.367372706  t Stat 
-
4.775205559  t Stat 
-
8.685532812  
P(T<=t) one-tail 0.011894166 ?? P(T<=t) one-tail 0.02058284 ?? P(T<=t) one-tail 0.006498975 ??
t Critical one-tail 2.91998558  t Critical one-tail 2.91998558  t Critical one-tail 2.91998558  
P(T<=t) two-tail 0.023788332  P(T<=t) two-tail 0.04116568  P(T<=t) two-tail 0.01299795  
t Critical two-tail 4.30265273   t Critical two-tail 4.30265273   t Critical two-tail 4.30265273   
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Table 2.2: 
  AS 
IFNγ 
Stimulated 
Control 
1.08mM C-
AS 1.08 C/F AS 
4.32uM C-
AS 4.32 C/F AS 
6.48uM C-
AS 6.48 C/F AS 
  78 12.18 66 75 24 61 29 42 
  73 8.19 68 78 24 64 37 32 
  83 8.19 64 83 27 45 10 21 
average 78.00 9.52 66.00 78.67 25.00 56.67 25.33 31.67 
stdev 5.00 2.30 2.00 4.04 1.73 10.21 13.87 10.50 
sqrt n=3 1.73 1.73 1.73 1.73 1.73 1.73 1.73 1.73 
std. error 2.89 1.33 1.15 2.33 1.00 5.90 8.01 6.06 
 
1.08mM CvsCF     4.32mM CvsCF     6.48mM CvsCF     
t-Test: Paired Two Sample for Means t-Test: Paired Two Sample for Means t-Test: Paired Two Sample for Means 
               
  Variable 1 Variable 2   Variable 1 Variable 2   Variable 1 Variable 2 
Mean 66 78.66666667 Mean 25 56.66666667 Mean 25.33333333 31.66666667 
Variance 4 16.33333333 Variance 3 104.3333333 Variance 192.3333333 110.3333333 
Observations 3 3 Observations 3 3 Observations 3 3 
Pearson 
Correlation 
-
0.618589574   
Pearson 
Correlation 
-
0.989158483   
Pearson 
Correlation 0.704772278   
Hypothesized 
Mean Difference 0   
Hypothesized 
Mean Difference 0   
Hypothesized 
Mean Difference 0   
df 2   df 2   df 2   
t Stat -3.98348238   t Stat 
-
4.597372226   t Stat 
-
1.111890898   
P(T<=t) one-tail 0.028812967 * P(T<=t) one-tail 0.022099905 * P(T<=t) one-tail 0.190964977   
t Critical one-tail 2.91998558   t Critical one-tail 2.91998558   t Critical one-tail 2.91998558   
P(T<=t) two-tail 0.057625934   P(T<=t) two-tail 0.04419981   P(T<=t) two-tail 0.381929954   
t Critical two-tail 4.30265273   t Critical two-tail 4.30265273   t Critical two-tail 4.30265273   
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AS vs 1.08mM CF   AS vs 4.32mM CF   AS vs 6.48mM CF   
t-Test: Paired Two Sample for Means t-Test: Paired Two Sample for Means t-Test: Paired Two Sample for Means 
               
  Variable 1 Variable 2   Variable 1 Variable 2   Variable 1 Variable 2 
Mean 78 78.66666667 Mean 56.66666667 78 Mean 31.66666667 78 
Variance 25 16.33333333 Variance 104.3333333 25 Variance 110.3333333 25 
Observations 3 3 Observations 3 3 Observations 3 3 
Pearson 
Correlation 0.618589574   
Pearson 
Correlation -0.93006235   
Pearson 
Correlation 
-
0.523611673   
Hypothesized 
Mean Difference 0   
Hypothesized 
Mean Difference 0   
Hypothesized 
Mean Difference 0   
df 2   df 2   df 2   
t Stat 
-
0.285714286   t Stat 
-
2.467018702   t Stat 
-
5.816968957   
P(T<=t) one-tail 0.400985246   P(T<=t) one-tail 0.066218816   P(T<=t) one-tail 0.014152298 ??
t Critical one-tail 2.91998558   t Critical one-tail 2.91998558   t Critical one-tail 2.91998558   
P(T<=t) two-tail 0.801970491   P(T<=t) two-tail 0.132437632   P(T<=t) two-tail 0.028304597   
t Critical two-tail 4.30265273   t Critical two-tail 4.30265273   t Critical two-tail 4.30265273   
IFNg stimulated vs 1.08mM C   IFNg stimulated vs 4.32mM C   IFNg stimulated vs 6.48mM C   
t-Test: Paired Two Sample for Means t-Test: Paired Two Sample for Means t-Test: Paired Two Sample for Means 
               
  Variable 1 Variable 2   Variable 1 Variable 2   Variable 1 Variable 2 
Mean 66 9.52 Mean 25 9.52 Mean 9.52 25.33333333 
Variance 4 5.3067 Variance 3 5.3067 Variance 5.3067 192.3333333 
Observations 3 3 Observations 3 3 Observations 3 3 
Pearson 
Correlation 0   
Pearson 
Correlation -0.5   
Pearson 
Correlation 0.228967996   
Hypothesized 
Mean Difference 0   
Hypothesized 
Mean Difference 0   
Hypothesized 
Mean Difference 0   
df 2   df 2   df 2   
t Stat 32.06693549   t Stat 7.646052837   t Stat -2.02463436   
P(T<=t) one-tail 0.000485537   P(T<=t) one-tail 0.008339182   P(T<=t) one-tail 0.090096003   
t Critical one-tail 2.91998558   t Critical one-tail 2.91998558   t Critical one-tail 2.91998558   
P(T<=t) two-tail 0.000971074   P(T<=t) two-tail 0.016678364   P(T<=t) two-tail 0.180192006   
t Critical two-tail 4.30265273   t Critical two-tail 4.30265273   t Critical two-tail 4.30265273   
 
 70 
VITA 
 
     Mindi Huguet Faubion was born in Metairie, Louisiana, on May 19, 1979.  She grew 
up in Kenner, Louisiana, and attended Alfred Bonnabel High School in Metairie from 
1993 – 1995.  She also attended Louisiana School for Math, Science, and the Arts 
(LSMSA) in Natchitoches, Louisiana, from 1995 – 1997.  She received her diploma from 
LSMSA in May 1997.  She enrolled in Louisiana State University in Baton Rouge where 
she completed her Bachelor of Science in Biological Engineering in May 2002.  She 
gained research and work experience as a Research Associate in the Civil and 
Environmental Engineering Department under the soon to be Dr. Emerald Roider.  She 
began working on her Master of Science in Biological and Agricultural Engineering in 
June 2005 and her degree will be awarded in May 2007. 
